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 تحديد النماط الجينية و التغيرات الوراثية في الجين ما قبل الرئيس و موقع التحكم
 في الجين الرئيس في فيروس التهاب الكبد الوبائي )ب( في المرضى الفلسطينيين
المصابين بالتهاب الكبد الوبائي )ب( المزمن ومضاعفات المرض على الكبد 
إعداد: سوسن صدقي سعيد
إشراف: د. محمود عبد الرحمن سرور
ملخص
 هناك ثماني أنماط جينية لفيروس التهاب الكبد الوبائي )ب(, والتي تمتاز بتوزيع جغرافي مميز لكل منها. و يبدو
 أن هذه النماط الجينية تؤثر على التطور السريري للمرض. في حين أن التغيرات الو راثية في الجين ما قبل
(  َقْد تتنب ُأ بتطويَر السرطاِن الكبدي. PCB وفي موقع التحكم الساسي في الجين الرئيس )CPالرئيس ِ ) )
  عينة تم جمعها في منطقة الضفة الغربية. و قد صنف  المرضى إلى ثلث051في هذه الدراسة، تم دراسة 
 ( سرطان الكبد )ع =3( و )72( تشمع الكبد )ع = 2(, )811( التهاب الكبد المزمن النشط )ع = 1مجموعات, )
(. ولدراسة النماط الجينية لفيروس التهاب الكبد الوبائي )ب( تم استخدام  تقنية تفاعل البلمرة المتسلسل ))5
 ( فقد تمتG  لتحديد سبعة أنماط جينية, .بينما النمط الجيني الثامن  )S المتعدد والمتداخل والمحددة للجيٍنRCP
 63( والذي يحتوي على صيغة مميزة لهذا النمط ناتجة عن إدخال erocدراسته في موقع الجين الرئيس )
 ( في الجيِن الرئيس. تم التحقق من النتائج السابقة بتحليل تسلسل الحماض النووية لهذه النماطpbنيوكليوتيدة )
  لدراسة الطفرات أو التغيرات  الو راثية فيPLFRو كذلك بتحليل التطور النوعي. في حين استخدمت تقنية))
(.PCB وفي موقع التحكم الساس في الجين الرئيس )CPالجين ما قبل الرئيس ِ ) )
   )هما الكثر انتشارا في منطقة الضفة47, ٪( A( و 3,52 ٪( Dو قد أظهرت الدراسة أن النمطين الجينيين  
 A +Dالغربية / فلسطين, إضافة إلى وجود انتشارا كبيرا و ملحوظا للنماط المختلطة و خاصة النمطين 
  فقد وجدت كجزء من عدوى من أنماط مختلطة ولكن ليس كنمط وحيد.  وC  و B(. أما النمطين 3,53٪(
 ( مقارنة72 من 91أظهرت العدوى المختلطة انتشارا أكبر بين المرضى الذين يعانون من تشمع الكبد )
 (. و قد أظهرت الدراسة أيضا أن نسبة عالية من مرضى321 من 77بالمرضى الذينل يعانون من تشمع الكبد )
ivx
 . ول سيما المرضى المصابين بعدوى مختلطة نتيجة النمطينgAeBHالتهاب الكبد الوبائي لديهم سلبية ل 
(.1 ,17٪( A+D
 ( بنسبة أعلى منPCB  , فقد وجدت الطفرة )stniarav 51 nodocوerocerp و PCBوفيما يتعلق بالطفرات 
  ما بين(30.0<p)الطفرات الجينية الخرى بين المرضى الفلسطينين, وتم إيجاد علقة ذات دللة إحصائية 
طبيعة النماط الجينية لللتهاب الكبد الوبائي )ب( وطفرة في لساسا موقع التحكم الجين الرئيس  )
لفيروس الكبد )ب(, ومن ناحية أخرى أظهرت هذه الدراسة عدم وجود علقة إحصائية ما بين الطفرة ).(PCB
( والنماط الجينية. ولكنها أظهرت شيوعا أكثر في المرضى الفلسطينين الذين يعانون من تشمع الكبد الوبائي.CP
 هو الكثر انتشارا إضافة إلى وجود ارتفاع ملحوظ فيDوفي النتيجة, فقد بينت هذه الدراسة إن النمط الجيني  
   بين المرضى الفلسطينيين. و تشير هذه النتائج أيضا إلى إنA+Dانتشار النماط المختلطة ول سيما النمطين 
 (CP)الصابة بالنماط المختلطة قد يرتبط بمضاعفات سريرية  لللتهاب الكبد الوبائي . كما أن وجود طفرة 
 ( يعتبرPCB الطفرة ) يعتبر كمؤشر ايجابي للدللة عن تشمع الكبد وسوء الحالة السريرية, في حين أن وجود 
كمؤشر سلبي لتطور سرطان الكبد.
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Hepatitis B virus genotypes and pre-core/core-
promoter mutations in Palestinian patients with 
chronic HBV and liver complications
By: Sawsan Sudqi   Said
 Supervisor: Dr. Mahmoud A.  Srour
Abstract
There are eight genotypes (A-H) of hepatitis B virus (HBV). The HBV genotypes show 
distinct geographic distribution and have been shown to influence the clinical course of 
infection.  Genetic mutations in the Pre-core C (PC) and basal Core Promoter (BCP) 
may predict the development of hepatocellular carcinoma.
In this study, we have genotyped 150 HBV clinical isolates from West Bank region, 
Palestine.  Patients  were  categorized  into  three  groups,  (i)  chronic  active  hepatitis 
(n=118), (ii) liver cirrhosis (n=27) and (iii) hepatocellular carcinoma (n=5). Genotyping 
was  performed  by  multiplex  nested-PCR  using  genotype-specific  primers 
complementary to pre-S1/S gene for A-F genotypes. While genotype G was genotyped 
by  nested  PCR  using  primers  specific  for  a  36_bp  insertion  in  the  core  gene. 
Genotyping was verified by DNA sequencing and phylogenetic analysis.  PCR-RFLP 
analysis was used to investigate PC / BCP mutations. 
The most prevalent genotypes were genotype D (25.3 %) and A (4.7 %) in the West 
Bank  region/Palestine.  Remarkably  a  high  prevalence  of  mixed  HBV  genotypes-
infections  mainly  due  to  A+D (35.3  %)  were  observed.  Genotypes  B  and  C  were 
observed only as part of a mixed infection but not as a single genotype. Infection with 
mixed genotypes  was more  predominant  among patients  with liver  cirrhosis  (19/27) 
xiv
than patients without cirrhosis (77/123). The prevalence of negative HBeAg (68 %) was 
higher than positive HBeAg among our study population. However, mixed genotypes 
particularly  A+D  (71.1  %),  tend  to  predominate  among  negative  HBeAg  patients 
compared to positive HBeAg patients.
Concerning the BCP mutation and precore region/ codon 15 variants, the BCP mutation 
was  the  predominant  mutation  among  HBV  isolates  analysed  in  this  study.  A 
statistically significant correlation was observed between the HBV genotypes and BCP 
mutation  (p<0.03).  Analysis  of the correlation  between the HBV genotypes  and PC 
mutation (p<0.16) and codon 15 variants (p<0.16), showed no significant correlation 
(p<0.16). But PC mutation tends to occur more predominantly among cirrhosis patients 
than CAH patients. 
This study showed that genotype D as the most prevalent one, and a markedly high 
prevalence  of  mixed  A+D  genotypes’  infections  among  Palestinian  patients  with 
chronic  HBV. These findings  indicate  that  mixed genotypes’  infection  is  associated 
with a higher risk for development of liver complications or bad clinical outcome (bad 
prognosis). The PC mutation is a positive predictive marker for liver cirrhosis and the 
presence of BCP mutation (G1896A) is a negative predictor for HCC.
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1I Introduction
Hepatitis B virus (HBV) infection is a global public health problem. Of the two billion 
persons worldwide who come in contact with HBV, 400 million fail to resolve acute 
viral infection and become chronic carriers. Seventy five percent of these live in Asian 
countries (Zuckerman & Zuckerman, 2000; Seeger, et al., 2007). Infection with HBV 
can lead to severe liver complications such as cirrhosis and hepatocellular carcinoma 
(HCC) (Lin & Kao, 2008).
Human HBV, a prototype strain of the family Hepadnaviridae, is a circular, partially 
double-stranded DNA virus of approximately 3200 nucleotides and contains four open 
reading frames. HBV strains isolated worldwide have been classified into nine different 
serological subtypes, (ayw1, ayw2, ayw3, ayw4, ayr, adw2, adw4, adrq+ and adrq) 
(Stuyver, 2000; Kao, 2002) and eight different genotypes (A-H) (Schaefer, 2007; 
Seeger, et al., 2007) reflecting the genetic variability of HBV. The HBV genotypes 
have distinct geographical distribution and some genotypes correlate with the severity 
of liver disease (Sugiyama, et al., 2007; Yuan et al., 2007).
HBV mutants have recently been identified in patients with acute, fulminant or chronic 
infections. Mutations in the basic core promoter (BCP) of HBV and pre-core region 
were previously reported in association with severe chronic hepatitis (Yuan, et al., 
2007). The prevalence of the pre-core mutation (PC) is variable, being high in the 
Mediterranean region and in the Far East and rare in the USA and northern Europe 
(Hadziyannis, 2001). There is a clear association between HBV genotypes and PC/BCP 
mutations. The genotyping of HBV can predict the risk of adverse outcomes (fulminant 
2disease, cirrhosis, and HCC) and can influence decision-making in management of 
HBV patients (Kidd-Ljunggren, 2002; Kato, et al., 2005).
I.1 HBV genome
HBV has a partially double-stranded DNA genome that is covalently linked to the viral 
reverse transcriptase (RT) at the 5' end of the full length negative strand (Delius, 1983). 
The complete genome is 3020-3320 nucleotides long (for the full length negative 
strand) or 1700-2800 nucleotides long (for the short length positive strand), which is 
incomplete and lacks from 15-50 % of its nucleotide complement. The double stranded 
DNA is held in relaxed circular configuration by overlapping of several hundred 
nucleotides at the 5’ extremities of the negative and positive strands, forming a direct 
repeat sequence of complementary base pairs (Shafritz & Lieberman, 1984). The 
double stranded genome has a nick at a unique site on full length negative strand 
opposite at a position 242 nucleotides downstream from the 5' end of the positive strand 
(Fig 1) (kidd-Ljunggren,  2002). 
Figure 1. HBV genome map. Four main classes of transcripts (arrows) the longest of which 
corresponds to pregenomic RNA (brown). Variations in 5´end positions for the 2.1 and 3.5 kb 
size classes are shown with blue and red dots, respectively. Colored boxes represent protein-
coding regions.  DR1 and DR2 are  10-12  bp  direct  repeat  sequences  which play a  role  in 
priming the synthesis of the minus- and plus-strand DNA (Kidd-Ljunggren, 2002).
3I.2 Structure of HBV virion
HBV genome contains four Open Reading Frames (ORFs) encoding: the envelope (Pre 
S1, Pre S2, S), core (core, pre core), polymerase and X protein. The S-gene (nt 2848 to 
nt 833; type ayw3) codes a 226 aa protein, named major antigen (S protein or HBs Ag). 
The preS2 gene codes a 55 aa protein, which together with the previous major antigen 
form the medium antigen (M protein). The preS1 gene codes a 108 aa protein which 
together with the previous medium antigen form the large antigen (L protein). The C-
gene (nt 1814 to 2450) codes the core protein (HBcAg) which forms the viral 
nucleocapsid. The pre-core gene (nts 1816-2457) codes for the pre-core protein or the 
e-antigen (HBeAg).  Both the HBcAg and HBeAg are important diagnostic tools and 
can be used to determine the status of ongoing HBV infections. The smallest viral X-
gene (nt 1374 to 1836) encodes the HBx or X protein which is required for infection in  
vivo and probably has various gene-regulating functions. The polymerase gene (nt 2307 
to 1621) codes the viral DNA polymerase (Fig 1) (Kreutz, et al., 2002).  
HBsAg is found in several forms in serum, 22-nm spherical aggregates and filamentous 
or tubular structures of 22-nm in diameter and up to 1000 nm long. Both of these 
structures are composed specifically of the viral envelope protein (HBsAg) and do not 
contain nucleic acids. A third structure, present in lesser amounts in serum, is 
comprised of an outer envelope and inner core (or nucleocapsid) and contains both 
DNA and protein. The latter structure, the so-called Dane particle, is 42 nm in 
diameter, has the morphologic appearance of a virus, and represents the infectious 
hepatitis B virion (Shafritz & Lieberman, 1984).
4I.2.1 HBV surface proteins
The HBV surface or S-coding region is divided into three parts by two internal 
initiation codons: the pre-S1, pre-S2, and S regions. The production of the three forms 
of surface protein (L, M and S) is controlled by two tandem promoters. The upstream 
pre-S1 promoter controls the transcription of a 2.4-kb transcript that encodes L protein 
only. The downstream S promoter, 240 bp away, specifies transcripts with 
heterogeneous 5' termini, with the largest transcript encoding the M protein and the 
remaining transcript encoding the S protein (Huang, et al., 2006).
I.2.2 HBV pre-core and core proteins
The pre-core/core region encodes hepatitis B e antigen (HBeAg) and core antigen 
(HBcAg). These two proteins are also derived by alternative initiation of translation at 
two in-frame AUG codons. The internal AUG encodes the 21-kD C protein, the 
structural polypeptide of the viral capsid, whereas the upstream AUG directs production 
of the 24-kD PC protein. The PC region encodes a signal sequence, which directs the 
chain into the secretory pathway. As the chains traverse the Golgi complex, cleavage by 
cellular proteases generates HBeAg, a 16-kD fragment that is secreted into the blood. 
The HBeAg is not required for viral assembly or viral replication but it might exert a 
role in the regulation of the immune response against HBV, particularly against the 
core protein (Ganem & Prince, 2004; Bruss, 2007).
I.2.3 HBV DNA polymerase and X proteins
The pol coding region is specific for the viral DNA polymerase or reverse transcriptase 
(RT), a multifunctional enzyme involved in DNA synthesis and RNA encapsidation. 
5The RT has three functional domains and a hinge region, known as the spacer. The 
three domains are: the N-terminal terminal protein domain (TP), the RT domain and the 
C-terminal RNase H domain. The X open reading frame encodes the viral X protein 
(HBx), which modulates the host-cell signal transduction and can directly and indirectly 
affect host and viral gene expression. X-protein activity is absolutely required for the in  
vivo replication and spread of the virus (Ganem & Prince, 2004; Beck & Nassal, 2007).
I.3 HBV replication cycle
Hepatocytes are the primary site of viral replication. In addition, lymphocytes are a 
second reservoir for virus persistence. During initiation of infection the viral particles 
contain predominately relaxed-circular DNA (rcDNA) with a complete minus strand 
and a partially synthesized plus strand as well as a small amount of double-stranded 
linear DNA (DSL) genomes. Following transport of the viral genome into the host cell 
nucleus the rcDNA genome with RT attached to the 5'end of the minus strand and a 
short RNA attached to the 5' end of the plus strand, is converted to the covalently 
closed circular DNA form, called CCC DNA. During this process, both the RT and the 
RNA are removed. The CCC DNA serves as the transcriptional template for host RNA 
polymerase II. This enzyme generates a series of genomic and subgenomic transcripts 
(Seeger & Mason, 2000).
The replication  cycle of HBV include attachment, endocytosis and fusion of the virus 
particle to hepatocytes, delivery of the released nucleocapsid to the nucleus, release and 
repair of the partially double stranded DNA genome by cellular enzymes, transcription 
and transport of pre-genomic and subgenomic viral RNAs, translation of the pre-
genomic (core and polymerase) and subgenomic (surface proteins and X-protein) 
6RNAs, encapsidation of the pre-genomic RNA and the polymerase into RNA-
containing nucleocapsids, reverse transcription into DNA containing particles that are 
either re-transported into the nucleus or enveloped and secreted as virions (Fig 2). Once 
partially double-stranded DNA has been produced, nucleocapsids can undergo a 
maturation event that facilitates their acquisition of an outer envelope via budding into 
the ER (Seeger & Mason 2000; Ganem & Prince, 2004).
Figure2. The Replication Cycle of HBV.  HBV virion bind to surface receptors and are 
internalized. Viral core particles migrate to the hepatocyte nucleus, where their genomes are 
repaired to form a covalently closed circular DNA (cccDNA) that is the template for viral 
messenger RNA (mRNA) transcription (Ganem & Prince, 2004).
I.4 Pathogenesis of HBV infection 
The clinical spectrum of HBV infection ranges from subclinical to acute symptomatic 
hepatitis or rarely fulminant hepatitis during the acute phase. Chronic infection is 
defined as the persistent presence of HBsAg in the serum of an individual for 6 months 
or longer. Chronic infection occurs in 90 % of infants infected at birth, 30 % of 
7children infected at an age of 1 - 5 years, 6 % of persons infected after 5 years of age 
(Robinson, 1995; Mhoney & Kane, 1999). Only 3 to 5 % of adults remain chronically 
infected and the remainders have acute infections resulting in viral clearance (Lee, 
1997). Humans with persistent HBV infection have high levels of viral replication in 
more than 95 % of the hepatocytes in the liver, and up to 1 × 1010/ml viral particles and 
5 × 1012/ml non-infectious surface antigen particles in serum (Huang, 2006).
I.4.1 Primary infection 
In primary infection, HBsAg becomes detectable in the blood after an incubation period 
of 4 to 10 weeks, followed shortly by antibodies against the HBV core antigen (anti-
HBc antibodies), which early in infection are mainly of the IgM isotype. Viremia is well 
established by the time HBsAg is detected, and virus titers in acute infection are very 
high, frequently 109 to 1010 virions per ml. Circulating HBeAg becomes detectable in 
most cases. Notably, in most acute hepatitis cases, the infection can be cleared from 
virtually all hepatocytes without massive hepatic destruction, with clearance of the 
infection, the viral antigens HBsAg and HBeAg disappear from the circulation, and 
free anti-HBs antibodies become detectable. However, low levels of HBV DNA in the 
blood may persist for many years, if not for life. It is not known whether this DNA 
contains the entire HBV genome, or even whether it is contained in virions (Ganem & 
Prince, 2004).  
I.4.2 Chronic infection
In persistent HBV infection HBsAg remains in the blood and virus production 
continues, often for life. However, levels of viremia in chronic infection are generally 
8substantially lower than those during primary infection (Ganem & Prince, 2004). The 
prognosis for many chronic carriers of HBV who were infected with HBV in the 
adulthood is poor. The natural history of HBV persistence suggests that there is an 
ongoing immune attack on infected cells in the liver, an attack that is usually inadequate 
to eradicate infection altogether, but that does reduce the number of infected cells and 
thereby lowers the circulating viral load. About 10 to 25 % of patients will die of either 
liver cancer or cirrhosis (tissue scarring). While smaller number of patients particularly 
those infected as adults, will die or require liver transplantation due to rapidly 
progressing liver disease leading to hepatic failure (Seeger & Mason, 2000).
The widely held view that circulating viral DNA disappears when anti-HBe antibodies 
appear is incorrect. The latter idea reflects the fact that, for many years, HBV DNA was 
measured by relatively insensitive hybridization methods with a detection limit of 105 to 
106 virions per ml. However, with the implementation of the polymerase-chain-reaction 
(PCR) method for detection and quantitation of HBV DNA, it’s now known that at least 
70 to 85 % of people with anti-HBe antibodies have detectable viral DNA in the 
circulation, typically in the range of 103 to 105 virions per ml, and sometimes higher. 
The HBeAg negative carriers are a heterogeneous group. Most such carriers have low 
levels of viral DNA, relatively normal levels of alanine aminotransferase, and a good 
prognosis (Ganem & Prince, 2004). 
I.4.3 Hepatocellular Carcinoma
Chronically infected subjects have a risk of hepatocellular carcinoma that is 100 times 
as high as that for non-carriers. Within the HBsAg positive group, HBeAg positive 
carriers have the highest risk of hepatocellular carcinoma. Even, carriers with anti-HBe 
antibodies have a substantial risk of cancer. Screening for HCC, with monitoring of α-
9fetoprotein levels and six-monthly radiographic examination should be considered for 
patients at increased risk of developing HCC. However the screening test of liver 
cancer is imperfect, i.e. α-fetoprotein has an excellent negative predictive value, but its 
positive predictive value ranges from 9 to 30 percent (Ganem & Prince, 2004; Buster & 
Janssen, 2006).
I.5 Mode of transmission 
 The most important mode of HBV transmissions is perinatal from mother to her baby. 
The other common modes of HBV transmissions include sexual contact; sharing 
toothbrushes or razors, sharing unsterilized needles among drug addicts, body or ear-
piercing, tattooing, and acupuncture. Furthermore HBV is able to remain on any 
surface it comes into contact with for about a week without losing infectivity 
(Robinson, 1995; Hollinger & Liang, 2001). Unlike the HIV virus, HBV transmission 
can also occur in settings of continuous close personal contact, such as among family 
members living together (Aitken & Jeffrie, 2001). 
I.6 Diagnosis of HBV infection
Thirty years ago, the diagnosis of chronic hepatitis B (CHB) was thought to require the 
presence of hepatitis B e-antigen (HBeAg), as a reliable and sensitive marker of 
hepatitis B virus (HBV) replication. Individuals positive for hepatitis B surface antigen 
(HBsAg) but negative for HBeAg were considered to have a non-replicative HBV 
infection, and if their liver enzymes were normal or nearly normal they were referred to 
as asymptomatic or healthy HBsAg or HBV carriers. Figure 3 shows typical patterns of 
serologic and molecular markers in both acute self-limited and chronic HBV infection 
(Ganem & Prince, 2004).  
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Figure 3. Patterns of serologic and molecular markers in HBV infection. Typical levels of 
alanine  aminotransferase  (ALT),  HBV  DNA,  hepatitis  B  s  and  e  antigens  (HBsAg  and 
HBeAg),  and anti-HBc, anti-HBe, and anti-HBs antibodies are shown in acute and chronic 
HBV infection. From (Ganem & Prince, 2004).
 In the early 1980s it became apparent that HBV could replicate in the absence of 
HBeAg. Patients from the Mediterranean area, although negative for HBeAg and 
positive for antibodies to HBeAg (anti-HBe), were reported to have CHB with 
replicating HBV. The term anti-HBe-positive or HBe Ag negative CHB was then 
proposed and subsequently became widely accepted. In 1989 the molecular basis of this 
form of CHB was discovered with the identification of HBV mutations preventing 
HBeAg formation from an otherwise normally replicating HBV (Jalali1& Alavian, 
2006).
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Recently, diagnosis of HBV based on a combination of biochemical, serological, 
virological and DNA tests and histological features have been used to diagnose and 
classify HBV infection. HBV DNA may be detected in serum using methods that 
employ DNA hybridization with or without signal amplification and the results of these 
tests may be expressed qualitatively or quantitatively (The EASL Jury, 2003).
 
I.7 Treatment 
Hepatitis B virus (HBV) infections are treated with antiretroviral drugs such as 
interferon, lamivudine (Buster & Janssen, 2006). Interferon-alpha was the only 
therapeutic choice for more than 20 years, but the overall response rate is < 30 %. 
However, in the advent of nucleoside/nucleotide analogues, lamivudine (LMV), 
adefovir (ADV) and more recently entecavir (ETV) have been approved for the 
treatment of chronic hepatitis B (Lung Lai, et al., 2006). Lamivudine is given orally, 
inhibits HBV reverse transcriptase activity and suppresses HBV DNA synthesis. It is 
very clear that prophylactic treatment with this drug when commenced before 
chemotherapy for solid tumors or haematological malignancies is highly effective in 
preventing reactivation in HBsAg positive patients. Problems arise with the emergence 
of resistant mutants in 14–32 % of patients after one year of therapy and up to 70 % 
after four years (Leemans, et al., 2007). However, to date, there have been no reports 
on the efficacy of adefovir and entecavir in the prevention or treatment of HBV 
reactivation. (Lubel, et al., 2007).
I.8 Prevalence of HBV 
Of the two billion persons worldwide who come in contact with HBV, 400 millions fail 
to resolve acute viral infection and become chronic carriers (Zuckermann & 
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Zuckermann, 2000; Seeger, et al., 2007). The world can be divided into three areas 
where the prevalence of chronic HBV is high (> 8%), intermediate (2-8 %), and low 
(<2 %) (The EASL Jury, 2003). The prevalence rate of HBV in Palestine was found to 
be 3.4 % in 2000 for all the population above 8 years of age (Ramlawi & Preventive 
Medicine Team, 2000). This rate can be considered as intermediate prevalence 
according to the WHO classification.
I.9 Classification   of HBV
HBV exhibits genetic variability which gives rise to the well recognized serotypes and 
genotypes of the virus. In addition, virus variants may arise during replication as a 
result of nucleotide misincorporation and in the absence of any proof–reading capacity 
by the viral polymerase (Zeng, et al., 2004).
I.9.1 HBV serotypes
The first classification of HBV isolates was done by serotyping. Within the S-gene 
different alleles or antigenic determinants have been recognized a, d, y, w (four sub 
determinants w1 to w4 are described), r and q. The “a” determinant is the major 
immunogenic region (aa 124 to 147) of HBsAg and is part of all HBs-subtypes. The 
determinants d/y and r/w are mutually exclusive epitopes. This leads to four main 
subtypes designated as ayw, ayr, adw, and adr or nine minor subtypes of the small 
HBsAg (Kao, 2002). The reagents used in many HBsAg diagnostic assays are directed 
against epitopes in the “a” determinant, the immunodominant region of HBsAg. The 
ability to detect HBsAg therefore was of obvious importance for the safety of blood 
supply, while serotyping was useful for epidemiological studies (Kay & Zoulim, 2007). 
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I.9.2 HBV genotypes
The first sequence of a complete HBV was published in 1979. By the end of the 1980s, 
enough full length genome sequences had accumulated in the databases to enable 
classification of HBV strains by genomic sequence rather than by surface protein 
antigenicity. Okmoto and his coworkers analyzed 18 full length genomes and divided 
them into four genotypes, named A to D. HBV genotypes were defined based on 
divergence of nucleotide sequences exceeding   8 % in the entire genome or 4 % in S 
gene (Fang, et al., 2004, Yuan, et al., 2007). Another four genotypes have been 
identified, E to H. The diversity within the genotypes has lead to the division of some 
genotypes into subtypes. To date the HBV genotypes are divided into 24 sub- 
genotypes that differ by at least 4 % from each other (Glebe, 2007). These genotypes 
have unique insertions/deletions that may have the potential to alter their replication 
ability (Sheldon, et al., 2006). Each genotype has canonical size, ranging from 3,182 nt 
for genotype D to 3,248 nt for genotype G. It is interesting to note that genotype F and 
perhaps genotype H, both lie on the same branch of phylogenetic tree that includes 
animal HBV, which may suggest that these human genotypes arose from zoonotic 
infection (Kay & Zoulim, 2007).
         
I.10 Geographical distribution of HBV genotypes
The evolution of HBV is strikingly highlighted by geographical distribution of the 
genotypes. Epidemiological studies suggest that these genotypes are common in 
different parts of the world with various frequencies as follows: genotype A in Western 
Europe and North America, genotype B in North and Southeastern Asia,  genotype  C 
in Asia and Pacific, genotype D in Southern Europe (Mediterranean countries) and 
Middle East, genotype E in Africa, and genotype F in South America and Alaska, 
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genotype G in some European countries and North America, and genotype H has been 
recently reported from Central America ( Lai, 2003; Palumbo,  et  al., 2007).
However, the distribution of HBV genotypes has not been determined among 
Palestinian patients with CHB. Previous studies that were carried out in the 
Mediterranean countries such as Turkey, Israel, Egypt and Italy found genotype D as 
the predominant genotype in patients with CHB (Kao, et al., 2000; Saudy, et al., 2003; 
Sunbul & Leblebicioglu, 2005).
A recent study by Zerki et al. (2007) indicated the predominance of genotypes D (37.1 
%) and B (25.7 %) and a relatively high prevalence of mixed-genotype infections in 
15.7 % of 70 Egyptian patients with chronic acute hepatitis. In the former report, the 
mixed genotypes-infections were mainly caused by A/D (7.1 %), but other 
combinations of genotypes were also detected such as C/D, B/D and B/C. Another 
study by Ayed et al. (2007) showed the predominance of genotype D among chronic 
Tunisian patients of hepatitis B virus and that infections caused by mixed genotypes 
accounted for 12.2 % of all chronic HBV infections.
I.11 HBV genotypes and correlation with clinical outcomes 
Several research attempts have been reported to find a correlation between a particular 
genotype and severe liver disease, but the results were controversial. Preliminary 
studies in Asia suggest that genotype C is associated more frequently with severe liver 
disease and HCC than genotype B. Genotype B appears to be associated with 
seroconversion from HBeAg to anti-HBe at a younger age than genotype C. The 
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genotypes may also affect response to antiviral therapy as genotypes A and B appear to 
have greater rates of antiviral response to interferon (IFN)-alpha therapy than D and C. 
Thus, genotyping of HBV can predict the risk of adverse outcomes (fulminant disease, 
cirrhosis, and HCC) or can influence decision-making in management of the HBV 
patients (Kao, et al., 2000; Kato, et al., 2005).
I.12 HBV mutants and their clinical significance 
HBV is a DNA virus and its replication requires an active viral reverse transcriptase 
/polymerase enzyme. The reverse transcriptase (for both HBV and human 
immunodeficiency virus) is believed to lack proof-reading function that is common to 
other polymerases. Indeed, HBV exhibits a mutation rate more than 10-fold higher than 
other DNA viruses (Jalali, & Alavian, 2006).
Naturally occurring mutations have been identified in all viral genes and regulatory 
elements. Most notably mutations in the genes coding for the structural envelope and 
nucleocapsid proteins, the HBeAg and HBsAg, may result in infection or viral 
persistence despite the presence of antibodies against HBsAg (anti-HBs). Mutations in 
the gene encoding the pre –core/core protein (pre-core stop codon mutant) result in loss 
of HBeAg (HBeAg minus mutant) and seroconversion to antibodies (anti-HBe) with 
persistence of HBV replication (Yuan, 2007; Huang, 2006). Mutations in the core gene 
may lead among others to an immune escape due to a T cell receptor antagonism. 
While mutations in gene coding for polymerase /reverse transcriptase can be associated 
with viral persistence or resistance to therapy by nucleotide analogues (Keeffe, et al., 
2006).
16
I.13 Mutations in the pre-core region 
The major HBV variants have been described with mutations in the pre-core region 
(PC) that prevent HBeAg synthesis despite continuing production of infectious-virions. 
The PC mutation is a G to A substitution at nt 1896 (A1896G), which creates a 
premature stop codon in the PC region. This mutation is also located at the highly 
conserved encapsidation (e) signal, which forms a secondary structure (stem-loop) in 
the pg RNA that is essential for initiation of encapsidation within the viral replication 
cycle. The G1896 forms a base pairing with nucleotide 1858 at the base of the stem 
loop. In HBV genotypes B, D, E, G and some C strains the nucleotide 1858 is a 
thymidine; therefore the stop codon stabilizes the e-structure (Sheldon, et al., 2006; 
Abbas, et al., 2006). Instead, the A1896 mutation is restricted to HBV isolates that have 
T instead of C at nt 1858, and is most commonly found in association with HBV 
genotypes which are more frequent in patients infected with B, D and E genotypes, and 
rare in patients infected with other genotypes (Fig 4).
Figure 4: Pre -core mutation and HBV genotype. From (Jalali & Alavian, 2006).
However, in the event of impaired base pairing when C-1858 tries to pair with A-1896, 
there is decreased encapsidation of pg RNA and decreased replication. The prevalence 
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of the A1896 mutant varies in different geographical regions, according to the 
distribution of HBV genotypes with T1858, and is not found in HBV genotypes with 
C1858. Therefore, T1858 predominates in all none A genotypes. (Jalali & Alavian, 
2006).
I.14 Mutations in the core promoter region
 The most common basal core promoter (BCP) mutations involve two nucleotide 
substitutions: A to T at nt 1762 and G to A at nt 1764. The BCP mutation has been 
predominantly found in Japan and Hong-Kong and was shown to down regulate the 
transcription of the precore mRNA and therefore decrease the expression of HBeAg. 
Patients with BCP mutants compared with those with wild-type have also been shown 
to have a higher risk for development of HCC. It has been demonstrated further that 
HBV genotype C is frequently associated with BCP mutations. Furthermore, the BCP 
mutations may induce not only amino acid change in X protein but also an alteration of 
HBV gene expression. The alternation of X protein might play a role in 
hepatocarcinogenesis, because its coding sequence overlaps regions of crucial 
importance for viral replication such as enhancer II and the BCP. Additionally, BCP 
mutations may give rise to HCC through probably other unknown pathways that are not 
well understood yet (Yuen, et al., 2004).
It is important to elucidate the interplay between HBV genotypes and BCP mutations 
since both are associated with the development of HCC. There is also a possible 
association between HBV genotypes and pre-core and core promoter mutations and 
earlier studies have suggested that genotyping of HBV can predict the risk of adverse 
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outcomes (fulminant disease, cirrhosis, and HCC) or can influence decision-making in 
management (Kao, et al., 2000; Kato, et al., 2005).
Currently, HBV genotypes and mutants can be determined by several methods, 
including direct DNA sequencing, restriction fragment length polymorphysim (RFLP), 
line probe assay, PCR using genotype-specific primers, colorimetric point mutation 
assay, and enzyme –linked immunosorbent assay for genotype specific epitopes. Direct 
sequencing is the most accurate and permits detection of the common as well as 
uncommon mutations but is also the most expensive and tedious (Schaefer, 2005 Is this 
2005 or 2007?). HBV genotyping and detection of pre core/ core mutations should be 
simple, accurate and specific to facilitate clinical application.
I.15 Objectives of the study 
Chronic hepatitis is an important medical problem in Palestine. With the 
implementation of vaccination against HBV in the national vaccination program for 
newborns since 1995, the incidence rate of hepatitis B carriership has markedly 
decreased from 67.5 per 100,000 in 2000 to 53 in 2004 with an annual average 
incidence rate of 56.1 per 100,000 in the last five years. However, Palestine is 
considered as moderately endemic area for HBV carriers, (Ministry of Health, 2005).
However, the distribution of HBV genotypes among Palestinian patients with CHB has 
not been determined. Furthermore, the distribution of HBV mutants within the pre-core 
and core promoter regions among chronic Palestinian patients has not been determined 
yet. 
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Therefore, the objectives of this study are: 
1. To determine the prevalence of HBV genotypes (A to H) among Palestinian patients 
with chronic infection.
2. To asses the correlation between HBV genotypes and liver complications such as 
cirrhosis and hepatocellular carcinoma. 
3. To investigate the clinical significance of mixed HBV genotype infections.
4. To detect the major pre-core and core promoter mutations among chronic HBV 
Palestinian patients and their correlation with HBV genotypes as well as with the 
clinical outcomes.
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IV.I Discussion
HBV infection is a global health problem and is a continuously increasing burden in 
developing countries. Recently, Hepatitis B genotyping has received more attention and 
research throughout the world. Hepatitis B virus has been classified into eight 
genotypes based on intergroup divergence of 8 % or more in the complete nucleotide 
sequence (Schaefer, 2007; Purdy, et al., 2008). The distribution of HBV genotypes may 
vary with time and with population immigration. The clinical significance of HBV 
genotypes on the clinical outcomes of HBV infection has been partially clarified. 
Several studies reported that HBV genotypes may differ in their serologic reactivity, 
pathogenicity, virulence, their association with HBV core antigen, HBeAg 
seroconversion, activity of liver disease, and response to therapy (Kao, et al., 2002; 
Idrees, et al., 2004; Tong, et al., 2007; Lin & Kao, 2008, Balsano & Alisi, 2008).
Previous reports have studied the correlation between HBV genotypes and mutations in 
the precore and core promoter regions that abolish or decrease the production of HBe 
Ag. Although, the findings were not conclusive in some studies, other studies have 
found a correlation between the core promoter and precore mutations and the clinical 
outcomes of the HBV infection (Kuang, et al., 2005). The occurrence of the precore 
mutation seems to be a strategy of the virus to evade the host immune response 
(Rezende, et al., 2005). Thus permitting the persistence of viral replication and 
maintenance of hepatic necro-inflammatory activity. However, the HBeAg negative 
state was predominant among Asian population and the frequency of precore mutations 
was significantly higher among HBeAg negative compared to HBeAg positive patients 
(Premchandra, et al., 2003).
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In this study, the prevalence of HBV genotypes and precore/core mutations were 
studied in 150 chronic HBV patients. Among our study population, genotype D (25.3 
%) was the predominant HBV genotype in chronic HBV palestinian patients. While 
genotype A was observed in a small proportion of patients, 4.7 %. Genotypes B and C 
were observed only as part of a mixed infection but not as a single genotype. The latter 
results agree with the prevalence of HBV genotypes in the Mediterranean and Middle 
East region. Remarkably, a high prevalence of mixed infections was observed in this 
study (64.7 %) and was attributed mainly to D+A co-infections (35.3 %). 
Recent HBV genotyping reports originating from Mediterranean and Middle East 
countries such as Egypt (Saudy, et al., 2003; Zekri, et al., 2007), Saudi Arabia (Abdo, 
et al., 2006), Tunisia (Ayed, et al., 2007), Morocco (Sbai, et al., 2007) and Turkey have 
demonstrated that HBV genotype D is the most common genotype circulating in these 
populations (Serin et al., 2005). Additionally, a high frequency of HBV genotype D 
(96%) and a low frequency of genotype A (4%) were reported in “Israel” (Ben-Ari, et  
al., 2004). Although the latter reports have demonstrated that in addition to the 
common genotype D, other genotypes are also present, albeit at a lower and variable 
frequencies. Indeed, the molecular heterogeneity of HBV genotypes is being 
increasingly reported worldwide (Onganer, et al., 2006). Table 17 summarizes the 
distribution of different HBV genotypes and mixed genotypes (see further discussion 
below) in Mediterranean countries as well as other Asian countries for comparison.
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Table 17. Prevalence of HBV genotypes and mixed genotypes in different Mediterranean 
and Asian countries. 
Country Study Population Prevalence of HBV genotypes References
Egypt Chronic carrier HBV Predominance D  Saudy , et al., 2003
Egypt Pediatric cancer patients 
with acute and chronic 
active HBV infection
D (37.1 %), B (25.7 %)
Mixed (15.7 %; mainly A+D)
Zekri, et al., 2007
Saudi 
Arabia
Chronic HBV patients 
(CAH, cirrhosis, HCC)
D (81.4 %), A (1.4 %) 
C (1.4 %) , E (5.7 %), Mixed (10 %; 
includes ADG, DE, DF, ADFG )
(Abdo, et al., 2006)
Tunisia Chronic carrier HBV D (84.75 %), B (0.6 %), A (0.6 %) 
 C (1.82 %), Mixed (12.2 %)
Ayed, et al., 2007.
Morocco Chronic  HBV D (97.5 %), A (2.5 %) Sbai, et al.,  2007
Pakistan Chronic HBV carriers C (41.07 %), A (21 %), B (17.86 %)
D (8.03 %), Mixed (7.14 %)
Idrees, et al., 2004
China HBV carrier patients with 
HBV related-liver disease
B (48.0 %), C (40.8 %), A (0.8 %)
D (0.8%), Mixed (9.6 %; all are B+C)
Zumbika, et al., 2005
Malaysia Chronic HBV carriers B (56.9 %), C (31.4 %)
Mixed (7.8 %)
Lim, et al., 2006
Since the beginning of HBV genotyping, it was noted that HBV genotypes show a 
distinct geographical distribution. In this regard, earlier reports of HBV genotyping 
have shown that a single genotype-infection is usually the major genotype circulating 
in the respective geographic region with other mixed  genotype-infections (usually 2) 
constituting a minor proportion of HBV infections (Lindh, et al., 1996; Lim, et al., 
2006; Tong, et al., 2006; Mello, et al., 2007; Sbai, et al., 2007). The presence of 
different patterns of HBV genotypes in many countries have been partly attributed to 
the well-known waves of immigration that have occurred over time in the respective 
country (Palumbo, et al., 2007). The geographical distribution of HBV genotypes in 
earlier studies is summarized in Table 17. 
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Remarkably, a high prevalence of mixed infections was observed in this study (64.7 %) 
and was attributed mainly to D+A co-infections (35.3 %). However, other 
combinations were also detected and included D+C (0.7 %), A+C+D (10 %), A+B+C 
(0.7 %), B+C+D (1.3 %) and A+B+C+D (16.7 %). Similar finding was reported by 
Hannoun et al. (2002) who found a mixed genotype infection in 67 % among his study 
population of 30 HBeAg-positive patients treated with Interferon. However, the 
findings of a high frequency of mixed genotypes in this study and by Hannoun et al. 
(2002) are in contrast with most earlier reports who found mixed genotypes for 
example in 0.0 % (Tong, et al., 2006; Sbai, et al., 2007), 0.8 % (Kao, et al., 2001), 1.6 
% (Zeng, et al., 2004), 10.9 % (Kato, et al., 2003), 15.7 % (Zekri, et al., 2007), 17.3 % 
(Olinger, et al., 2006) and 17.5 % of the respective study HBV isolates (Chen, et al., 
2004) (see Table 17 for geographic distribution of mixed genotypes). 
Little is known about the nature and origin of mixed genotypes (Coinfection). But 
based on the higher frequency of mixed infections, it was suggested that chronic carrier 
HBV patients often become superinfected with additional strains or that de novo 
infection with genotype mixtures is common (Hannoun, et al., 2002). The presence of 
mixed genotypes also may depend on the routes of acquired HBV infection which are 
usually not known for most patients (Hannoun, et al., 2002). Coinfection may be 
acquired first by injection drug use in subjects, who then introduced it into HBV carrier 
population by other routes. The latter explanation is plausible, because it is difficult for 
a superinfecting genotype to establish itself against a genotype that is already present 
throughout the liver (Hannoun, et al., 2002). Also our results indicated that the mode of 
HBV infection is unknown in the majority of patients (58.8 %), but 28.1 % of patients 
have acquired infection via a household member (Table 8). These results indicate that 
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despite the well known routes of HBV transmission, most patients are still not aware of 
these routes or more specifically of the event that transmitted the infection. 
The coexistence of different patterns of HBV genotypes and mixed genotypes probably 
reflects the distribution of Palestinian people (mostly refugees) in different countries 
and their mixing through return or social relations. In this study some patients have 
admitted that before return in late 1990s to Palestine they have been living for long 
periods mainly in Tunisia, Kuwait, and Lebanon (data not shown).
 
The method for genotyping influences the detection of mixed genotypes (Kato, et al., 
2003). Common HBV genotyping methods include direct DNA sequencing (Serin, et  
al., 2005) or RFLP analysis (Zeng, et al., 2004) of preS1/S2/S region, RFLP analysis of 
core region (Hannoun, et al., 2002), PCR with genotype-specific primers (Naito, et al., 
2001) and genotype specific probes assay (GSPA) (Kato, et al., 2003). The PCR-RFLP 
method showed a prevalence of coinfection of 0.8% in a highly endemic region (Kao, 
et al., 2001), while a genotype specific probes assay (GSPA) showed a prevalence of 
coinfection of 10.9 % from countries where HBV is not highly endemic (Kato, et al., 
2003). In a recent report from Turkey, all of the 50 HBV chronic patients genotyped by 
DNA sequencing of the preS1 through S region, showed genotype D and none showed 
mixed genotypes (Serin et al., 2005). On the other hand, using PCR with genotype-
specific primers for genotyping of 164 Egyptian patients (Zekri, et al., 2007) and 70 
Tunisian patients (Ayed, et al., 2007) with chronic HBV infection, showed a 
prevalence of mixed genotypes of 15.7 % and 12.2 %, respectively.  The DNA 
sequencing probably detects the predominant genotype, while the RFLP analysis fails 
to detect any quasi genotype constituting less than 10 % of the genotype mixture. While 
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HBV genotyping using RFLP-PCR failed in 18 samples out of 158 samples, which 
were successfully genotyped by a nested PCR using genotype-specific primers, which 
reflects the fact that nested PCR much more sensitive than PCR-RFLP (Leblebicioglu, 
et al., 2004).  However, technically the PCR with genotype-specific primers (this 
study) and genotype-specific probe assay (Kato, et al., 2003) are highly sensitive and 
capable of detecting quasi genotypes, provided the method is properly optimized. In 
this study, when some samples with mixed genotypes (D+A) were further analyzed by 
DNA sequencing, only the predominant genotype D was observed. While when 
genotype-specific PCR amplicons were analyzed by DNA sequencing, the results were 
concordant with the PCR results.
Also several explanations are provided for the source of mixed genotypes, conclusive 
experimental evidences are not available yet. However, the detection of several 
recombinant HBV arising from different combinations of genotypes, may suggest that 
they arise as a result of mixed genotype infection (Schaefer, 2007). Additionally, 
Schaefer (2007) has raised the possibility that mixed genotypes may arise as a 
consequence of fast adaptation of HBV to a certain genetic and immunologic 
environment in different human populations. 
The detection of coinfection by different HBV genotypes has an important implication 
for prognosis and treatment of CHB. The presence of mixed genotypes has been found 
to be associated with a more severe liver disease compared with infections with a single 
HBV genotype (Ayed, et al., 2007).
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The prevalence of negative HBeAg cases among CHB patients seems to vary 
geographically and in correlation with the geographical distribution of HBV genotypes. 
In Italy, 41 % of patients with CHB during the period of 1975-1985 were HBeAg 
negative but in the last decade this has increased to 90 % (Jalali & Alavian, 2006 ). 
There is a worldwide increase in the prevalence of negative HBeAg cases. In this study 
the distribution of negative HBeAg cases (68 %) was higher than positive HBeAg (31.5 
%) cases. Analysis of the correlation between HBV genotypes and the status of HBeAg 
showed a predominance of mixed genotypes (mainly A+D) among negative HBeAg 
patients (71.1 %) compared to positive HBeAg patients.
CHB infection with negative HBeAg is frequently associated with precore and core 
promoter mutants (Yuan, et al., 2007). The predominant precore mutation involves a 
G-to-A change at nucleotide (nt) 1896 (G1896A), which creates a premature stop 
codon and abolishes the synthesis of HBeAg. Another common precore variant 
includes the C1858/T1858, where this variant nucleotide pairs with nucleotide at 1896 
to form the stem-loop structure that acts as a binding site for viral polymerase on the 
HBV pgRNA. Genotype A contains invariably the C1858 variant, which favors the 
presence of G at position 1896 (wild type). The latter observation explains the lower 
frequency of precore mutation at position 1896 in Northern Europe, where HBV 
genotype A predominates (Laperche, et al., 2006). On the other hand the non-A HBV 
genotypes (B, C, D and E) usually have the T1858 variant which pairs with A at 
nucleotide 1896 (Zumbika, et al., 2005). Thus precore mutations at position 1896 is 
frequently observed in the Mediterranean region where HBV genotype D predominates 
(Leblebicioglu, et al., 2004).
65
The dual basal core promoter (T1762 and A1764) mutations have been reported to 
reduce HBeAg production by approximately 50 to 70 %. However, it is controversial 
whether the T1762 and A1764 mutations lead to the seroconversion of HBeAg to the 
negative phenotype (Chen, et al., 2005).
In this study, it was observed that the basal core promoter mutation occurred at a higher 
percentage among HBV isolates (single mutant 17/135 or as a co-infection with Wt 
58/135) compared to the other precore mutation. Although no statistically significant 
correlation was found between the BCP mutation and HBeAg status, the percentage of 
BCP mutation (present in 55.5% of samples) was more predominant among negative 
HBeAg patients compared with positive HBeAg patients. The latter results are 
consistent with the findings reported by a recent Tunisian's study that also showed the 
predominance of BCP mutation among HBeAg-negative patients compared to the 
HBeAg–positive patients (65.4 % vs. 18.2%) (Ayed, et al., 2007).
Six out of seven (85.7%) cases with HBV genotype A detected in this study, contained 
the BCP mutation while only one case of genotype A (14.3 %) contained the wild type 
sequence at this position. A higher frequency of BCP mutation was also found among 
mixed genotypes (55.7%) compared to single genotype infections. Additionally, a 
statistically significant correlation was observed between the BCP mutation and HBV 
genotypes (p<0.032) or serum HBV DNA levels (p<0.000). 
Regarding the PC mutation, we have found a significant correlation between the PC 
mutation (G1896A) and the patients’ age (p<0.001) as well as the serum HBV DNA 
level (p<0.001). No significant correlation was observed between the T1858/C1858 
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variant and the patients’ age, sex, HBV genotype, HBeAg status and serum HBV DNA 
level. Additionally, a significant correlation was observed between the serum HBV 
DNA levels and positive HBeAg cases compared to negative HBeAg (p <0.002).
The clinical significance of different HBV genotypes has become increasingly 
recognized in patients with different clinical outcomes, different genotypes may be 
associated with different rates of progression from acute to chronic HBV infection. A 
recent study demonstrated that infection with HBV genotype A is associated with acute 
hepatitis whereas infection with the most prevalent genotypes B and C lead to chronic 
infection among Japanese patients (Baig, et al., 2007). Genotypes B and C are the most 
prevalent variants in Taiwan, and it has been reported that genotype C is associated 
with a more severe liver disease compared to genotype B (Chen, et al., 2005). 
However, a recent report by Zumbika, et al. (2005) from China indicated a high 
prevalence of mixed genotypes (B+C) infection among patients with severe chronic 
hepatitis and in liver cirrhosis patients (25 vs. 17.7 %). 
In this study, it has been observed that older patients are at a higher risk of developing 
liver cirrhosis than younger patients and that CAH is more predominant among 
younger patients. Also infection with mixed genotypes was more predominant (23/32) 
among patients without CAH (including HCC & liver cirrhosis patients) than those 
with CAH (73/118). While infection with mixed genotypes was more predominant 
among patients with liver cirrhosis (19/27) than patients without cirrhosis (77/123). 
Taken together, these findings indicate that mixed genotype infection is associated with 
a higher risk for development of liver complications or bad clinical outcome (bad 
prognosis). 
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The serum HBV DNA level showed a significant correlation with the clinical status of 
HBV infection in patients with CAH compared to those without CAH (p<0.009). Also 
patients with cirrhosis have a significantly higher levels of serum HBV DNA than those 
without cirrhosis (p<0.038). These findings reflect the fact that patients with severe 
liver complications have higher levels of viral replication.
A significant correlation was also found between the PC mutation (G1896A) and 
presence of CAH (p<0. 0.013) or liver cirrhosis (p<0.001). Also the PC mutation is 
found more among liver-cirrhosis patients (11/24) than CAH patients (17/103). 
Analysis of the correlation between the BCP mutation and codon 15 variants, showed 
no significant correlation with CAH. However, codon 15 variants show more 
prevalence of C1858 variant among cirrhosis patients (7/19, 36.25 %) compared to 
patients without cirrhosis (18/98, 18.4 %). These findings show that PC mutation 
(G1896A) is a risk factor for development of severe liver complications. While the 
correlation between BCP and codon 15 variant needs further investigation and probably 
by a case-controlled prospective study.
Chronically HBV carriers have a 100 times increased risk of hepatocellular carcinoma 
compared to non-carriers (Ganem & Prince, 2004). HBsAg positively increases the risk 
of developing HCC by 10-fold and HBeAg positively by 60-fold. Whereas, a detectable 
HBV DNA level has a 4-fold increased risk of HCC. Generally, all categories of liver 
diseases showed male dominance; where it is well documented in HCC case. The HCC 
incidence is three to six times higher in males than in females, suggesting a tumorigenic 
effect of androgens (Baig, et al., 2007). 
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Of all the 150 study samples, only five patients have had HCC at the time of sample 
collection, patients in this study who developed HCC were solely males. A significant 
correlation between patients’ age (mean age in years 54.00 ± 4.85) and development of 
HCC was observed (p <0.005). These findings are in concordant with previous studies 
that have also found that older age (> 45 years) is an important determinant of HCC 
development (Pan & Zhang, 2005).
Four out of five HCC patients (80 %) have mixed genotypes compared to 63 % of HBV 
patients without HCC, and three out of four HCC patients (HBeAg values are available 
for only 4 of the 5 HCC patients) were negative for HBeAg. However, no significant 
correlation has been observed between the HCC and mixed genotypes, HBeAg status as 
well as PC mutation and codon 15 variants. However, the results indicate a high 
prevalence of mixed genotypes and HBeAg negative status among HCC patients. The 
lack of significant correlation can be attributed partially to the low sample size in case 
of HCC group. Moreover, we have observed a significant correlation between wild type 
BCP (G1896) and HCC (p<0.023), i.e., the presence of BCP mutation is a negative 
predictor of HCC. 
Furthermore, HBV is suggested to be directly carcinogenic because of the integration 
of HBV DNA into the host cellular DNA that may cause instability of host 
chromosomes in liver cells, interrupt cellular tumor suppressor genes, or cause 
alterations in the expression of cellular growth factors and/or apoptosis regulating 
genes (Michielsen , et al., 2005). It seems that the integration of the HBV genome 
regardless of genotype into host chromosome plays an important role in the 
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development of HCC, especially in non-cirrhotic patients with HBV infection, which 
may explain the lack of correlation between the HBV genotypes and development of 
HCC (Wang, et al., 2000; Abdo, et al., 2006). 
In conclusion, HBV genotype D was found to be the most common genotype in 
West Bank region/Palestine and a high prevalence of mixed HBV genotypes mainly 
due to A+D (35.3 %) was also found. Genotypes B and C were observed only as part 
of a mixed infection but not as a single genotype. These findings indicate that mixed 
genotypes’ infection is associated with a higher risk for development of liver 
complications or bad clinical outcome (bad prognosis). The distribution of negative 
HBeAg (68 %) was higher than positive HBeAg among our study population. The 
basal core promoter mutation occurred at a higher percentage among HBV isolates. A 
statistically significant correlation between the HBV genotypes and BCP mutation 
was observed. The wild type BCP (G1896) was significantly correlated with HCC 
and thus the presence of BCP mutation (G1896A) is a negative predictor for HCC. 
Additionally, the PC mutation is more predominant among cirrhosis patients than 
CAH Patients. Thus our results indicate that the PC mutation is a positive predictive 
marker for liver cirrhosis and indirectly for HCC; since it is already known that 15-40 
% of patients with liver cirrhosis will develop HCC. Further studies are needed to 
investigate the correlation between the mixed genotypes and clinical outcome as well 
as the type of treatment, probably via a case-controlled prospective study including a 
larger number of patients. 
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III Results
III.1 Patients
One hundred and fifty HBV patients were enrolled in this study. Patients were selected 
from all the governorates of West Bank, and the number of patients was representative 
for the population count for each governorate (Table 6). Selection of patients was 
performed randomly from chronic HBV patients presenting at one of the Public Health 
centers in the respective governorate between July 2004 and August 2006. Based on the 
clinical status, patients were divided into three groups: (i) chronic active hepatitis 
(n=118), (ii) liver cirrhosis (n=27) and (iii) hepatocellular carcinoma (n=5). The mean 
age of the patients was 35.92 ± 14.75 years and the study population included males 
(n=112) and females (n=38). The number of female patients, presenting at the Public 
Health centers collaborating with this study at the time of sample collection, was lower 
than male patients for unknown reasons. 
            Table 6. Geographical distribution of HBV patients included in this study.
No. of patients (%)Place of birth
35 (23.3 %)Ramallah
41 (27.3 %)Hebron
3 (2.0 %)Alquds
23 (15.3 %)Nablus
7 (4.7 %)Tulkarm
9 (6.0 %)Jenin
2 (1.3 %)Salfiet
23 (15.3 %)Bethlehem
2 (1.3 %)Tunisia
1 (0.7 %)Lebanon
1 (0.7 %)Kuwait
3 (2.0 %)Sample origin not identified
150 (100.0 %)Total
III.2 Distribution of HBV genotypes 
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For HBV genotyping, the multiplex nested PCR was used. The multiplex- nested PCR 
used specific primers for determination of the eight HBV genotypes (A through H). All 
samples used in this study were HBsAg positive and HBV DNA positive by PCR. 
However, following genotyping of the study samples, 142 samples were assigned to a 
specific genotype(s) while 8 samples were untypable (Table 7). Genotypes of HBV 
samples were determined by identifying the genotype- specific DNA bands on agarose 
gels. The three different second–rounds PCR amplicons (mix A, mix B and mix G) 
from each sample were separately electophoresed on a 2 % agarose gel. Mix A allows 
for the specific detection of genotypes A, B and C. The mix B allows for the specific 
detection of genotypes D, E and F, and mix G for specific detection of genotype G. The 
sizes of PCR amplicons were estimated according to the migration pattern of 50-bp or 
100-bp DNA ladder.
Figures 6 through 11 show representative agarose gels for mix A, B and G as well as 
PCR amplicons of all detected HBV genotypes in this study. The size of PCR 
amplicons representing the different HBV genotypes were as follows; 68 bp, 281 bp, 
122 bp and 119 bp for genotypes A (Figs 6-8), B (Figs 7-8 ), C (Figs 7-8 ) and D (Figs 
9-10), respectively, either as a single genotype or mixed genotypes (Table 7).
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Figure 6. Agarose gel electrophoresis pattern of “Mix A” PCR amplicons showing 
genotype A. Lane M: 100-bp Ladder; lane 1: Negative control; lanes 3, 6, 8, 13, 18: are 
positive for genotype A (68bp); and the remaining lanes were negative for Mix A, i.e., no 
genotype A, B or C was detected.
 
Figure 7. Agarose gel electrophoresis pattern of “Mix A” PCR amplicons showing 
genotype A, B and C. Lane M: 50-bp Ladder; lanes 2, 4, 9, 14, 19: showed mixed genotypes 
which include A (68 bp), B (122 bp) and C (281bp); lanes 10, 15: positive for genotypes A and 
C; Lane 16: positive for genotypes B and C; and the remaining lanes were negative for Mix A, 
i.e., no genotype A, B or C was detected. The Negative control lane was included in the same 
run and is not shown here because it was run on a second gel.
 M   1   2   3   4    5   6    7   8   9  10  11  12  13 14 15  16  17 18 19 
100 bp
100 bp
 M   1    2    3    4    5    6    7    8    9  10   11  12  13  14  15  16  17  18 19 
50 bp
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Figure 8. Agarose gel electrophoresis pattern of “Mix A” PCR amplicons showing 
genotype A,  B and C. Lane M: 50-bp Ladder; lanes 1, 3, 8, 14: showed mixed genotypes 
which include A (68 bp), B (122 bp) and C (281bp); lanes 6, 13: positive for genotypes A ; 
Lane 5: positive for genotypes B and C; and the remaining lanes were negative for Mix A, i.e., 
no genotype A, B or C was detected. The Negative control lane was included in the same run 
and is not shown here because it was run on a second gel.
Figure 9. Agarose gel electrophoresis pattern of “Mix B” PCR amplicons showing 
genotype D. Lane M: 50-bp Ladder; lanes 1, 2, 3, 4, 5, 6, 7, 8, 12, 13: are positive for genotype 
D (119 bp); and the remaining lanes were negative for Mix D, i.e., no genotype D, E or F was 
detected. The Negative control lane was included in the same run and is not shown here 
because it was run on a second gel.
100 bp
         1     2      3     4     5     6      7        8    9    10    11   12   13   M  
50 bp
50 bp
100 bp
  M   1    2    3    4    5    6    7   8   9   10 11  12  13 14 15 16 17
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Figure 10. Agarose gel electrophoresis pattern of “Mix B” PCR amplicons showing 
genotype D. Lane M: 50-bp Ladder; lanes 1, 3, 5, 7, 8, 9, 10, 12, 16: are positive for genotype 
D (119 bp); lane 6; Negative control; and the remaining lanes were negative for Mix D, i.e., no 
genotype D, E or F was detected. 
All the results for Mix G were negative for HBV genotype G (Fig 11). However, the 
specificity of Mix G PCR reaction was checked by including a pair of primers that 
generate an internal control fragment to verify the functionality for the Mix G PCR. As 
shown in Figure 11, all samples showed the internal control fragment of 406 bp.
M    1    2       3     4    5     6    7    8      9    10   11  12    13   14   15   16   M  
100 bp
50 bp
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Figure 11. Agarose gel electrophoresis pattern of “Mix G” PCR amplicons. Lane M: 100 
bp DNA ladder; lanes 1-18: in all lanes the genotype G-specific fragment was not detected but 
the fragment corresponding to the internal control (406 bp) was detected in all lanes. Lane 19: 
Negative control.  
This study showed that the majority of palestinian HBV patients were infected   with 
either genotype D (25.3 %) or A (4.7 %) (Table7). However, a high prevalence of 
mixed genotypes infections was observed and was attributed mainly to D+A infections 
(35.3 %). Genotypes B and C were observed only as part of a mixed infection but not 
as a single genotype (Table 7). However, in this study genotypes E, F, G and H were 
not detected.
Table7. Prevalence of HBV genotypes among palestinian HBV patients.
HBV Genotype No. of patients (%) No. of HBeAg(+) 
patients (%)
No. of HBeAg(-) 
patients (%)
A 7 (4.7 %) 3 (50.0 %) 3 (50.0 %) 
D 38 (25.3 %) 11 (37.9 %) 18 (62.1 %) 
A/D 53 (35.3 %) 11 (28.9 %) 27 (71.1 %) 
A/C/D 15 (10.0 %) 0 (100.0 %) 11 (0.0 %) 
A/B/C/D 25 (16.7 %) 8 (38.1 %) 13 (61.9 %) 
A/B/C 1 (0.7 %) 1 (100.0 %) 0 (0.0 %)
B/C/D 2 (1.3 %) 2 (0.0 %) 0 (0.0 %) 
D/C 1 (0.7 %) 0 (0.0 %)  1 (1.3 %) 
Non –type able 8 (5.3 %) 0 (0.0 %) 5 (100.0 %)  
Total 150 (100 %) 36 78 
III.2.1 Distribution of HBV genotypes based on HBeAg status
     400 bp
 M   1    2    3    4    5    6    7    8    9  10   11  12  13  14  15  16  17  18 19 
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Analysis of the distribution of HBV genotypes according to the clinical status of 
HBeAg showed that mixed genotypes, particularly A+D (71.1 %), tend to predominate 
among negative HBeAg patients compared to positive HBeAg patients (Table 7). The 
genotype D also was more predominant among negative HBeAg patients (62.1 %) and 
was only second to the mixed genotypes A+D (Table 7). 
Table 8 shows that there was no significant correlation between the HBeAg status and 
patients’ age and sex as well as any of the risk factors recorded in this study. However, 
the results indicate that in more than half of the patients, either positive or negative for 
HBeAg, the risk factor for transmission or acquisition of HBV infection is unknown 
(Table 8). 
Table 8. General characteristics of chronic HBV patients according to presence or 
absence of HBeAg in serum. 
HBeAg(+) HBeAg(-) P - value
No. of patients 36* 77*
Age 32.97 ± 14.34 35.36 ± 14.18 0.41
Sex M/F 25/11 58/20 0.58
Risk factors 0. 33
Household Member ( Non - 
Sexual)
14 (38.9 %) 18 (23.3 %)
Sex Partner 0 (0.0 %) 1 (1.3 %)
Perinatal 1 (2.8 %) 3 (3.9 %)
Dentist 0 (0.0 %) 4 (5.2 %)
Blood Borne Disease 0 (0.0 %) 4 (5.2 %)
Nosocomial 0 (0.0 %) 1 (1.3 %)
Unknown 21 (58.3 %) 46 (59.7 %)
*Represent the no. of patients for whom complete data presented in this table is available
III.2.2 DNA sequencing and phylogenetic analysis.
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Although the nested multiplex PCR used for genotyping has successfully genotyped the 
majority of the study samples, the remarkably high incidence of mixed genotypes has 
prompted us to refer to DNA sequencing to confirm the PCR results. For this purpose, 
selected samples representing all genotypes detected in this study were subjected for 
DNA sequencing. For DNA sequencing two types of DNA fragments were used. 
Firstly, a fragment covering most of the S-region (nts 203 to 704) was used for 
sequencing. Electronic genotyping using the NCBI HBV genotyping tool (available at 
www.ncbi.nlm.nih.gov/projects/genotyping/formpage.cgi; Rozanov, et al., 2004) or 
HBV STAR (available at www.vgb.ucl.ac.uk/starn.shtml; Myers, et al., 2006) indicated 
that genotype D is the predominant genotype circulating in West Bank. Additionally 
phylogenetic analysis showed that our isolates were closely clustered with genotype D 
(Gene Bank accession no. X65259 and M32138) (Fig 12).
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Figure 12. Consensus phylogenetic tree constructed on a 502 bp of the preS1 through S 
genes. HBV Genotypes and subtypes were retrieved from Gene Bank. The blue color shows 
HBV isolates from this study which were clustered with D subtypes. Alignments were obtained 
with clustal 1X (1.81) program. The statistical significance of the phylogenies constructed was 
estimated with the SEQBOOT program. The 100 data sets obtained were analyzed with the 
DNADIST program. While the observed nucleotide distance matrix was then processed with 
the NEIGHBOR program, and the tree was generated with the CONSENSE program. The 
numbers at the nodes represent the percentage of 100 bootstrap replicates that contained the 
cluster distal to the node.
Although the results of DNA sequencing analysis confirmed the presence of genotype 
D, but it did not yield conclusive results to confirm the presence of mixed HBV 
genotypes among our isolates. Because the DNA fragment used for DNA sequencing, 
was generated by a primer pair common to all genotypes, which probably amplifies 
preferably the most predominant genotype, i.e., genotype D. Since agarose gel 
electrophoresis of the primer-specific nested multiplex PCR showed, for most samples, 
that genotype D is the predominant one in case of mixed genotypes. Therefore, a 
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second type of DNA fragments were used, which included the genotype-specific PCR 
amplicons generated by the genotype-specific primers. For this purpose, two samples 
representative of each genotype detected in this study were selected for DNA 
sequencing. Phylogenetic analysis showed a 100 % concordance between the two 
genotyping assays; the nested multiplex PCR with genotype-specific primers and DNA 
sequencing (Figs 13-16).  
 A F 0 9 0 8 4 2
 S  1 7 4
 S  1 2 8
W e s t  B a n k  H B V  G e n o t y p e s  A
 A B 0 1 4 3 7 0
 X 5 1 9 7 0
 X 0 2 7 6 3
9 3
2 3
2 0
1 0 0
Figure 13. Phylogentic tree of two different genotype A (genotyped by primer-specific 
PCR) samples as well as HBV prototype and subtypes A retrieved from Gene Bank 
(accession no. are shown on the tree). The Gene Bank accession no. AB014370 represents the 
prototype of genotype A. 
 D 0 0 3 2 9
 A F 1 0 0 3 0 9
 S  1 0 0
 S  1 2 6
W e s t  B a n k  H B V  G e n o t y p e  B
 A B 0 3 3 5 5 4
1 0 0
6 4
1 0 0
Figure 14. Phylogenetic tree of two different genotype B (genotyped by primer-specific 
PCR)  samples  as  well  as  HBV prototype  and  subtypes  B  retrieved from Gene  Bank 
(accession no. are shown on the tree). The Gene Bank accession no. AB033554 represents the 
prototype of genotype B.  
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 A B 0 1 4 3 8 1
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W e s t  B a n k  H B V  G e n o t y p e  C
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Figure 15. Phylogenetic tree of two different genotype C (genotyped by primer-specific 
PCR)  samples  as  well  as  HBV prototype  and  subtypes  C retrieved from Gene  Bank 
(accession no. are shown on the tree). The Gene Bank accession no. AB014365 represents the 
prototype of genotype C. 
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Figure 16. Phylogenetic tree of two different genotype D (genotyped by primer-specific 
PCR)  samples  as  well  as  HBV prototype  and  subtypes  D retrieved from Gene  Bank 
(accession no. are shown on the tree). The Gene Bank accession no. X97848 represents the 
prototype of genotype D. 
Table 9 shows the demographic and virologic characteristics of HBV genotypes. There 
was no significant correlation between the HBV genotype and patients’ age, sex and 
serum DNA level. Analysis of the correlation between the HBeAg status and genotype 
shows a predominance of mixed genotypes among patients negative for the HBeAg, 
although this difference was not statistically significant (Table 9). 
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Table 9. Demographic and virologic characteristics of HBV genotypes.
Characteristic Genotype 
A
Genotype D Mixed NA* p-value
No. of Patients 7 38 97 8
Age yr (mean ± 
SD)
40.14 ± 
11.01
35.92 ± 15.08  35.98 ±15.09 31.50 ± 13.07 0.74
Male /Female 4/3 31/8 70/26 7/1 0.48
HBeAg, n (%) **n=6 **n=29 **n =74 **n =5 0.27
        + 3 (50 %) 11 (37.9 %) 22 (29.7 %) 0 (0.0 %)
        - 3 (50 %) 18 (62.1 %) 52 (70.3 %) 5 (100.0 %)
HBV-DNA 
level (mean ± 
SD)
4.72 ± 0.74 
log10
4.62 ± 1.66 
log10
5.05 ±  1.83 
log10
4.44 ± 1.83 
log10
0.53
*NA: not-typeable samples.
** Represent the no. of patients for whom HBV genotypes data presented in this table is 
available
III.3 Determination of pre-core, basal core promoter mutants and Codon 15 
variants
The three precore/core mutations were analyzed by a nested RFLP-PCR. All the 150 
study samples were subjected for analysis of the latter three mutations, but some 
samples failed to yield PCR amplicons in one or more of these mutation respective 
PCRs. Thus, Table 10 shows the frequency of basal core promoter (BCP) mutation, 
Codon 15 variants, and pre-core stop codon (PC) mutations in 135, 117 and 132 
patients, respectively. The basal core promoter mutation was found at a higher 
percentage among HBV isolates (single mutant 17/135 or as co-infection with mutant 
and wt 58/135) compared to the other two mutations.  
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Table 10. Frequency of basal core promoter and precore mutations among palestinian 
chronic HBV patients.
Basal Core promoter 
mutation 
(A/G 1762/4  T/A)
Codon 15 variants 
(C1858/T1858)
Pre-core stop codon mutation 
(G1896A or codon 28 
TGG>TAG)
Wild type 60 92* 104
Mutant 17 8** 14
Con- infections
(Mutant/ Wild 
type)
58 17 14
Total 135 117 132
*C1858 variant; **T1858 variant
Basal core promoter mutation: 
For analysis of BCP mutation, the nested RFLP-PCR amplicons were digested with 
BfuC1, which in the presence of the mutation generates a mutant-specific fragment of 
110 bp (Fig 17). The same PCR amplicon also contains a wild type restriction site in 
the majority of HBV isolates, and thus serves as an internal control for the BfuCI 
digestion reaction (Fig 17).  As shown in Table 11, there was a significant correlation 
between the BCP mutation and the HBV genotypes. The BCP mutation was more 
predominant among cases with A and mixed genotypes. Analysis of the correlation 
between the HBeAg status and the BCP mutation showed a predominance of BCP 
mutation among negative HBeAg patients compared to wild type, although this 
correlation was statistically not significant. 
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Figure 17. Agarose gel electrophoresis pattern of nested RFLP-PCR amplicons for the 
BCP mutation (A/G1762/1764T/A). Lane M: 100 bp DNA ladder; lanes; 1, 2, 3, 4, 6, 8, 9, 10, 
11, 12, 13, and 14: show the BCP mutant with the mutant-specific fragment of 110 bp; lanes 5 
and 7: show the wild type digestion pattern.
Table 11. Demographic and virologic characteristics of basal core promoter mutation 
(A/G 1762/1764 T/A).
Pre-Core G1896A/ codon 28 stop mutation: 
Characteristic BCP 1762/1764
Mutant & Co-infection
Wild Type P Value
No. of patients 75/135 60/135
Age yr (mean ± SD) 36.88 ± 15.01 36.51 ± 16.79 0.91
Male / Female 54/21 49/11 0.19
Genotype, n 0.03
A 6 1
D 13 19
Mixed 49 39
Not type -able 7 1
HBe Ag, n n=57 n=43 0.44
+ 17 16
- 40 27
HBV- DNA level 
(mean ± SD)
4.45 ± 1.56 log10 5.60 ± 1.83 log10 0.000
M     1     2         3     4      5      6      7      8     9     10      11     12    13   14
         200 bp
1000 bp   
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        300 bp
    100 bp
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The nested RFLP-PCR specific for the PC mutation was successful in 132 samples. 
The PCR amplicons were digested with Bsu36I and the presence of PC G1896A 
mutation was identified by the detection of the mutation specific fragments of 164 bp 
and 30 bp (Fig 18), while the presence of the undigested fragment of 194 bp indicates 
the presence of wild type genotype. As shown in Table 12, there was a significant 
correlation between the PC mutation and the patients’ age (p<0.001) as well as the 
serum HBV DNA level (p<0.001). Analysis of the correlation between the HBV 
genotypes and PC mutation, showed no significant correlation. However, the number of 
samples showing the PC mutation was low (28/132), and thus a larger sample size is 
needed to reach a conclusive result regarding this point.  
  
M           1         2          3           4           5          6         7
500bp
200bp
50bp
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Figure 18. Agarose gel electrophoresis pattern of nested RFLP-PCR amplicons specific 
for the PC (G1896A) mutation. Lane M: 50 bp DNA Ladder; lane 1: positive for the mutant 
and  show mutant  specific  fragment  of  160  bp;  lanes  2,  3,  4,  7:  wild  type  and  show the 
undigested fragment of 194 bp; lane 5: empty;  lane 6: show both the mutant and wild type 
pattern. The 30 bp fragment that accompanies the mutant specific fragment of 160 bp, can not 
be detected using the above gel.  
Table 12. Demographic and virologic characteristics of pre-core stop codon mutation 
(G1896A or codon 28 TGG>TAG). 
 
characteristic    Mutant  PC1896
(mutant & co-infection) 
  Wild type           P-value 
No. of patients 28/132 104/132 
Age yr (mean ± SD) 44.61 ± 15.26 33.60 ± 14.24 0.001
Male / Female 23/5 78/26 0.25
Genotype, n n=28 n=104 0.16
A 0 6 
D 11 22
Mixed 16 69
Not type -able 1 7
HBe Ag, n n=17 n=82 0.39
+ 4 28 
- 13 54 
HBV- DNA level 
(mean ± SD)
5.91 ± 1.33 log10 4.71 ± 1.77 log10 0.001
Precore region/ Codon 15 variants:
 The nested RFLP-PCR specific for codon 15 variants was successful in 117 samples. 
The amplicons were digested with EcoNI, and the detection of undigested fragment of 
208 bp indicates the presence of the C1858 variant while the detection of 178 bp and 30 
bp indicates the presence of T1858 variant (Fig 19).  As shown in Table 13, no 
significant correlation was observed between the T1858/C1858 variants and the 
patients’ age, sex, HBV genotype, HBeAg status and serum HBV DNA level. 
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Figure 19. Agarose gel electrophoresis pattern of  nested RFLP-PCR amplicons specific 
for the precore codon 15 variants (T1858/C1858). Lane M: 50 bp DNA ladder; lane 1 and 2: 
positive for the T1858 variant and show the specific fragment of 178 bp; lanes 4: show both the 
T1858 (178 bp) and C1858 (208 bp) variants. The 30 bp fragment that accompanies the T1858 
variant specific fragment of 178 bp, can not be detected using the above gel.  
Table 13. Demographic and virologic characteristics of pre-core codon 15 variants 
(C1858/T1858). 
Characteristic Codon 15             Mutant 
& Co-infection
(T1858 variant)
Wild Type
(C1858 variant)
P-Value
No. of patients 25/117 92/117 
Age yr (mean ± SD) 40.04 ± 12.235 35.51 ± 15.789 0.195
Male / Female 20/5 69/22 0.66
Genotype, n  n=25 n=92 0.16
A 3 3 
D 7 21 
Mixed 15 61 
Not type -able 0 7
HBeAg, n n=18 n=70 0.156
+ 8  19
- 10 51
HBV- DNA level 
(mean ± SD)
4.97 ± 1.85 log10 4.95 ± 1.80 log10 0.970
III.4. Serum HBV DNA level
The  presence  of  detectable  levels  of  serum  HBV  DNA  was  determined  by  a 
quantitative  PCR  method  on  the  COBAS-Amplicore  (Roche  diagnostics)  and  was 
M                1               2                  3            4
M        M           1                 2                   3               4              5 
6         7
200 bp 
50bp
   1000 bp  
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considered as one of the criteria for enrolment into this study. Table 14 summarizes the 
serum HBV DNA level and their correlation to the patients’ sex and HBeAg status. The 
results  show that  the DNA level  in patients  with positive HBeAg was significantly 
higher than those with negative HBeAg (Table 14; p<0.002). However, no significant 
difference in the HBV DNA levels was observed between male and female patients. 
Table 14. Demographic and virologic characteristics of baseline serum HBV DNA levels 
(mean ± SD; copies/ml).
characteristic Mean HBV-DNA levels p-value
Sex                                 0 .365
Male 4.95 ±  1.76 log10
Female 4.641 ± 1.65 log10
HBe Ag                               0 .002
+ (n=34) 5.63 ± 1.64 log10.                                        
- (n=75) 4.53 ± 1.72log10
III.5 Correlation between HBV genotypes and clinical outcomes in patients with 
chronic HBV 
Table 15 shows the statistical analysis of factors associated with the clinical outcomes 
in patients with chronic HBV infection. A significant correlation was observed between 
the presence or absence of CAH or cirrhosis and patients’ age. Where older patients are 
at a higher risk of developing liver cirrhosis than younger patients and that CAH is 
more predominant among younger patients. Additionally, no significant correlation was 
observed between HBV genotypes and presence or absence of CAH or cirrhosis. 
However, the results indicate that infection with mixed genotypes was more 
predominant among patients with CAH than those without CAH. While infection with 
mixed infection was more predominant among patients without liver cirrhosis than 
cirrhotic patients. Table 15 also shows that patients with CAH have a significantly 
lower levels of serum HBV DNA compared to those without CAH (p<0.009). While 
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patients with cirrhosis have a significantly higher levels of serum HBV DNA than those 
without cirrhosis (p<0.038). A significant correlation was also found between the PC 
mutation (G1896A) and presence of CAH (p<0.013) or cirrhosis (p<0.001).  Analysis 
of the correlation between the BCP mutation and codon 15 variants, showed no 
significant correlation with CAH or cirrhosis. 
Table 15. Statistical analysis of factors associated with clinical outcomes in HBV patients. 
CAH No CAH* P- value Cirrhosis No Cirrhosis P-value
No. of patients 118 32 27 123
Age, yr (mean ± 
SD) 31.35 ± 12.56 52.39 ± 9.60 0.000 52.08± 10.31 32.36 ± 13.14
0.000
Male/Female 85/33 27/5 0.155 22/5 90/33 0.37
Genotypes n=118 n=32 0.38 n=27 n=123 0.44
A 5 2 2 5
D 32 7 6 33
Mixed 73 23 19 77
Not type -able 8 0 0 8
HBe Ag, n n=92 n=23 0.32 n=18 n=96 0.35
- 61 17 14 64
+ 31 5 4 32
HBV- DNA 
level (mean ± 
SD)
4.71 ± 1.76 
log10
5.74 ± 1.50 
log10 0.009
5.60 ± 1.46 
log10
4.76 ± 1.78 
log10 0.038
BCP1762/1764 n=105 n=30 0.127 n=26 n=109 0.526
W 43 17 13 47
M 62 13 13 62
PC (G1896A) n=103 n=29 0.013 n=24 n=108 0.001
W 86 18 13 91
M 17 11 11 17
Codon 15 
variants 
C/T1858
n=93 n=24 0.109 n=19 n=98 0.072
W (C1858) 76 16 12 80
M (T1858) 17 8 7 18
No CAH* represent hepatocellular carcinoma & cirrhosis patients.
Furthermore, we have reported the type of antiviral treatment the patients received at 
the time of sample collection (data not shown). Where the majority of patients with 
CAH were  treated  with  Interferon  (24/118),  Epivirin  (17/118)  or  a  combination  of 
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Interferon and Lamivudine (24/118). While patients without CAH were mostly treated 
with Epivirin (16/32), and a lower number of patients in this group received Interferon 
(1/32) or Interferon and Lamivudine (4/32). But, still a good proportion of patients with 
(44/118)  or  without  (6/32)  CAH  received  no  treatment.   Regarding  patients  with 
cirrhosis,  a  lower  number  of  patients  compared  to  non-cirrhotic  patients  received 
antiviral  treatment  at  the time of sample collection.  Patients  with cirrhosis  received 
Epivirin  (16/27),  Interferon  and  Lamivudine  (3/27)  or  no  treatment  (3/27).  While 
patients  without  cirrhosis  received  Interferon (25123/),  Epivirin  (17/123),  Interferon 
and Lamivudine (47/123) or no treatment (25/123). Since, the type of treatment was 
reported at one point only; analysis of statistical correlation with liver complications is 
not useful and thus was not performed. We suggest that different groups of chronic 
HBV patients  receiving different antiviral  therapy are followed over a specific  time 
period and the type of liver complications studied, which should allows a more accurate 
investigation of the correlation between the type of treatment and liver complications. 
Table 16 summarizes the statistical analysis of factors associated with the development 
of HBV infection to HCC. Of all the 150 study samples, only five patients have had 
HCC at the time of sample collection. As shown in Table 16, HCC tend to develop at 
an older age among chronic HBV patients (p<0.005). Also patients with HCC tend to 
have a higher serum levels of HBV DNA (p<0.058). Remarkably, all of the four HCC 
patients typed for the BCP mutation showed the wild type pattern (p<0.023). Moreover, 
Table 16 shows that four out of five HCC patients have mixed genotypes and that three 
out of four HCC patients (HBeAg values are available for only 4 of the 5 HCC 
patients) were negative for HBeAg. The lack of significant correlation between the 
HCC and HBV genotype or HBeAg may be attributed to the lower number of HCC 
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cases included in this study. Moreover, no significant correlation was observed between 
HCC and the patients’ gender, PC 1896 mutation and the codon 15 variants. 
Table 16. Statistical analysis of factors associated with development of HCC.
HCC No HCC P value
No. of patients 5 145
Age, yr (mean ± SD) 54.00 ± 4.85 35.27 ± 14.58 0.005
Male/Female 5/0 107/38 0.185
Genotypes n=5 n=145 0.85
A 0 7
D 1 38
Mixed 4 92
Not type -able 0 8
HBeAg n=4 n=110 0.77
- 3 75
+ 1 35
HBV- DNA level 
(mean ± SD)
7.23 ± 2.08 log10 4.86 ± 1.74 log10 0.058
BCP 1762/1764 n=4 n=131 0.023
W 4 56
M 0 75
PC (G1896A) n=5 n=127 0.237
W 5 99
M 0 28
Codon 15 variants 
C/T1858
n=5 n=112 0.939
W (C1858) 4 88
M (T1858) 1 24
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II Materials and methods
II.1 Materials
All chemicals and reagents used were of Molecular Biology Grade. A list of chemicals 
and buffers, and solutions used in this study are shown in Tables 1 and 2, respectively. 
Table 1. Chemicals and reagents.
Chemical Source, country
Puregene  DNA Purification kit Gentra, USA
Wizard® SV Gel and PCR Clean 
System
Promega, USA
Big Dye ®Terminator Cycle 
Sequencing Kit
Applied Biosystems, USA
Guanidinium thiocynate Sigma, USA
Sodium citrate Finkeman
Sarcosyl Sigma, USA
2- mercaptoethnol Sigma, USA
Sodium acetate ICN
Agarose (ultra pure agarose) Invitrogen, Scotland
Tris base (99 %) Avocdo, Johnson Matty
Boric acid Himedia, India
EDTA (99 %) Avocdo, Johnson Matty
GoTaq ® DNA polymerase (5U/ µL) Promega, USA
dNTP's Mix ( 10 mM) Promega, USA
Ethidium Bromide (10 mg/ml) Sigma, USA
Table 2. Buffers and solutions.
  
Buffer Components
TE 10 mM Tris, pH 8.0, 1 mM EDTA
Solution D 4 M guanidinium thiocynate,  25 mM sodium citrate  (pH 7), 
0.5% sarcosyl, 0.1 M 2-mercaptoethanol
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All PCR primers used were obtained from Invitrogen (UK) and Metabion (Jerusalem) 
and the sequences of primers used are shown in Table 3.
Table 3. Primer sequences used for HBV genotyping by nested PCR
Primer name Primer sequence (position, specificity, and polarity) length
P1 5'-TCA CCA TAT TCT TGG GAA CAA GA-3'
(nt 2823-2845, universal, sense)1
23
S1-2 5'-CGA ACC ACT GAA CAA ATG GC-3'
(nt 685-704, universal, antisense ) 1
20
B2 5'-GGC TCM AGT TCM GGA ACA GT-3'
(nt 67-86, types A to E specific, sense) 1
20
BA1R 5'-CTC GCG GAG ATT GAC GAG ATG T-3'
(nt 113-134, type A specific, antisense) 1
22
BB1R 5'-CAG GTT GGT GAG TGA CTG GAG A-3'
(nt 324-345, type B specific, antisense) 1
22
BC1R 5'-GGT CCT AGG AAT CCT GAT GTT G-3'
(nt 165-186, type C specific, anti sense) 1
22
BD1 5'-GCC AAC AAG GTA GGA GCT-3'
(nt 2979-2996, type D specific, sense) 1
18
BE1 5'-CAC CAG AAA TCC AGA TTG GGA CCA-3'
(nt 2955-2978, type E specific, sense) 1
24
BF1 5'-GYT ACG GTC CAG GGT TAC CA-3'
(nt 3032-3051, type F specific, sense) 1
20
B2R 5'-GGA GGC GGA TYT GCT GGC AA-3'
(nt 3078-3097, types D to F specific, anti sense) 1
20
HBV-2160A 5'-CTG ACT AC T AAT TCC CTG GAT GCT GGG TCT-3'
(nt  2131-2160, antisense)2
30
HBHKF1 5'-ACG GGG CGC ACCTCT CTT TAC-3'
(nt 1519 to 1539, sense)3
21
HBV-1606S 5'-GCA TGG AGA CCA CCG TGA AC-3'
(nt 1606-1625, sense) 2
20
HBHKR2 5' AGC CAA AAA GGC CAT ATG GCA3'
(1917-1937, antisense )
21
HBV-1653 5'-CAT AAG  AGG ACT CTT GGA CT-3'
(nt1653-1672,  sense) 3
 20
HBV-2094A 5'-CAC CCA GGT AGC TAG AGT CAT CA-3' 23
22
(nt 2094-2116, antisense )4
HBV-2039A 5'-GTA TGG TGA GGT GAA CAA TG-3'
(nt 2058-2039 , antisense)3
20
YS1-S 5'-GCG GGG TTT TTC TTG TTGA-3'
(nt 203-221, sense)5
19
HBV-1680S 5'ATG TCG ACA ACC GAC CTT GA-3'
(nt 1680-1699, sense)3
 20
HBV-1888AS 5'CCC AAG GCA CAG CTT GGA GGC TCC TAC AGT-3'
(nt 1888-1859, antisense) 3
30
HBV-1865S 5'CAA GCC TCC AAG CTG  TGC CTT GGG TGG CCT T3'
(nt 1865-1895, sense) 3
31
The sequence of primers denoted by a superscript number were obtained from the 
following references: 1(Naito, et al., 2001), 2(Kato, et al., 2002), 3(Lindh, et al., 1996), 
4(described in this study), 5(Zeng, et  al., 2004).
The restriction enzymes used for detection of precore/ basal core promoter mutations 
were obtained form New Englan Biolabs (UK) (Table 4).
Table  4.  Restriction  endonucleases  used  for  detecting  HBV  pre-core  and  basal  core 
promoter mutations.
Restriction enzyme Recognition site Source
EcoNI 5'…CCTNN▼NNNAGG…3'
3'…GGNNN▲NNTCC...5' 
New  England Biolabs
Bsu36I 5'…CC▼TNAGG…3'
3'…GGANT▲CC…5'
New  England Biolabs
BfuCI 5'…▼GATC….3'
3'…..CTAG▲….5'
New  England Biolabs
II.2 Methods
II .2.1 Study design and data collection
The archives in governmental  medical centers in the different governorates of West 
Bank between July 2004 and August 2006 were reviewed for identification of patients 
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with  chronic  HBV.  Patients  with  chronic  HBV  included:  chronic  active  HBV, 
hepatocellular  carcinoma  and  patients  with  liver  cirrhosis.  One  hundred  and  fifty 
patients were selected. The following information for each patient was reported (see the 
Questionnaire in Appendix 1): patient’s gender, mean age (range), and the presence of 
liver complications such as liver cirrhosis (LC),  chronic active hepatitis  (CAH) and 
hepatocellular carcinoma. Selection of patients was in accordance with the distribution 
of HBV cases in various regions as recorded in the national  annual report  of HBV 
between 2004 and 2006, and correlated to the prevalence of HBV in the year 2000 (Fig 
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5). 
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Figure 5. The prevalence of positive HBsAg carriers distributed by districts in West Bank 
2000. From (Ramlawi & Preventive Medicine Team, 2000).
II .2.2 Criteria for patients' selection
Patients for this study were selected according to the following criteria: Patients whom 
age falls between 16 to 65 years old, HBsAg positive at least for a period of 6 months, 
HBeAg  or  anti-HBe  measured  (either  positive  or  negative),  HBV-  DNA  positive 
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(quantitative)  in  serum  and  serum  alanine  aminotransferase  (ALT)  and  aspartate 
aminotransferase  (AST)  levels  were  measured.  Personal  and clinical  information  of 
selected  HBV  patients  were  collected  by  asking  the  treating  physician  to  fill  the 
provided  HBV  questionnaire.  Questionnaires  were  filled  only  after  obtaining  an 
informed consent from the selected patients. 
II .2.3 Biochemistry and serologic markers
Liver  function tests,  ALT and AST were measured for most  patients  to  establish a 
baseline for patients’ examination by using a commercial kit (Diaysis, Biosystem kit) 
according to the manufacturer’s instructions. Serological testing for HBsAg, hepatitis B 
e-antigen (HBeAg), anti-HBe, anti-HBc IgM, anti-HBc IgG, anti-HBs were done for 
most patients enrolled in the study using commercial kits (Biokit,  Equipar, Organic, 
Human, and Atlas; respectively) per the manufacturer’s instructions.
II. 2.4 Detection of HBV DNA by PCR and viral load determination
Detection of HBV DNA and viral load determination was performed in serum from 150 
patients using a quantitative PCR technique on the COBAS-Amplicore machine (Roche 
Diagnosis System, USA) and HBV DNA detection kit for COBAS Amplicore (COBAS 
AMPLICORE HBV MONITOR Test, Roche Diagnosis System, USA), as a diagnostic 
test to confirm the presence of HBV infection as well as determine the viral DNA load. 
The test can quantify HBV DNA over the range of 60 to 38,000 International Units 
(IU)/ml  (300  to  200,000  HBV DNA copies  /ml).  The  HBV monitor  test  uses  the 
primers HBV-104UB and HBV-104D to define a sequence of 104 nucleotides within 
the highly conserved pre-Core /Core region of the HBV genome.
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II .2.5 Sample preparation and storage
Sera were collected from respective patients with HBV infection and stored at -35°C 
until used.
II. 2.6 Extraction of HBV- DNA from serum
Part of the nucleic acid extraction was carried out by using Gentra DNA extraction kit 
(Puregene Minneapolis, USA) according to the manufacturer's instructions. Briefly, for 
extraction of HBV-DNA, 100 µl serum was mixed with 300 µl Cell lysis solution (Tris, 
EDTA and sodium dodecylsulfate) and 1 µl Rnase was added and incubated at 37oC for 
10  minutes.  After  that  3  µl  of  protinase  K  (20  mg/ml)  was  added  to  the  lysate, 
incubated at 55oC for 1-2 hours and then chilled on ice for 1 minute.  The digested 
lysate was mixed with 200 µl of protein precipitation solution (Ammonium acetate) and 
centrifuged  at  14000  rpm  at  room  temperature  for  3  minutes  and  the  supernatant 
containing  the DNA was transferred  to  a  new tube.  The DNA was precipitated  by 
addition  of  500  µl  isopropanol  and  overnight  incubation  at  -20ºC,  followed  by 
centrifugation at 14000 rpm at 4ºC for 15 minutes. The DNA pellet was washed from 
the isopropanol traces with 700 µl of 70 % ethanol and with further centrifugation at 
14000 rpm at  4ºC for  5  minutes.  The  DNA pellet  was  air  dried  at  37ºC for  5-10 
minutes. The resulting pellet was resuspended in  25 µl DNA Hydration Solution (10 
mM Tris, pH 8, 1 mM EDTA) and was incubated at 37oC overnight or at 65oC for one 
hour and then subjected to nested PCR.
The  second  part  of  HBV  DNA  extraction  was  performed  by  Acid  Guanidinium 
Thiocynate phenol –chloroform (AGPC) method as described by (Chocmczynski & 
Sacchi,  1987).  Briefly,  200  µL  of  patient’s  serum  was  mixed  with  600  µL  of 
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denaturing  Solution  D (Solution  D contains  4  M guanidinium thiocynate,  25 mM 
sodium citrate, pH 7, 0.5 % sarcosyl, 0.1 M 2-mercaptoethanol) and 1/10 volume of 3 
M sodium acetate (pH 4.2-5.2). The latter mixture was mixed with an equal volume of 
phenol: chloroform (pH 8) and incubated at room temperature for 20 minutes. The 
mixture  was  centrifuged  at  13000  rpm at  room temperature  for  20  minutes.  The 
aqueous phase containing the DNA was transferred to a new tube, mixed with 0.5 
volume  of  chloroform and centrifuged  at  13000  rpm at  room temperature  for  20 
minutes.  For precipitation of DNA, the aqueous phase was mixed with 900 µL of 
isopropyl alcohol, incubated overnight at –20ºC, and further processed as described 
above for the Gentra DNA extraction kit. However, hydration of the DNA pellet was 
performed  by  adding  50  µL of  sterile  free-nuclease  water  at  37ºC  for  1  hour  or 
overnight, and then subjected to nested PCR.
  II .2.7 HBV Genotyping
Genotyping of HBV isolates was performed by multiplex- nested PCR using specific 
primers for determination of the seven HBV genotypes (A through H except G), based 
on S-region of HBV as described by Naito et al., (2001). The specificity of the results 
was confirmed by employing sequencing and phylogenetic analysis for representative 
samples. 
II. 2.7.1 Determination of HBV genotypes (A-F) by multiplex nested PCR of S 
region with specific primers
The sequences of PCR primers used in this study were described earlier by Naito, et al., 
(2001), and are shown in Table 3. For the first-round PCR, a 2 µl aliquot of processed 
serum specimens was subjected to 25 µl polymerase chain reaction (PCR) with the 
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following amplification  mixture:  each  reaction  contained  5 µl  of  5X GoTaq buffer 
containing 1.5 mM MgCl2, 0.2 mM of deoxynucleotide triphosphate mix, 0.3 µM of 
each of the common primer pair P1 and S1-2, 1U of Taq DNA polymerase (Promega, 
USA). The common primer pair (P1 and S1-2) hybridizes to a conserved consensus 
region in the S/preS-gene in all HBV genotypes. Thermal cycling was  performed as 
follows: initial denaturation at 94ºC for 4 minutes,  followed by 35 cycles, with each 
cycle  consisting  of  denaturation  at  94ºC for  30  seconds,  annealing  at  52ºC for  30 
seconds, extension at 72ºC for 1 minute, followed by a final extension at 72ºC for 5 
minutes. 
The amplicons (1097 bp) of first-round PCR were subjected to two second – round 
PCR reactions  called  Mix  A (detects  genotypes  A,  B  and  C)  and  Mix  B  (detects 
genotypes D, E and F). Mix A used the common universal sense primer (B2) and the 
genotype-specific  primers  (BA1R,  BB1R  and  BC1R  for  genotypes  A,  B  and  C, 
respectively), while mix B used the common antisense primer B2R and the genotype-
specific primers (BD1, BE1 and BF1 for genotypes D, E and F, respectively) (Naito, et  
al.,  2001;  Idrees,  et  al.,  2004).  However,  because  genotype  H  and  F  show  high 
sequence  homology,  they  were  amplified  using  the  same  primer  pair.  Thus 
discrimination between H and F should be further performed by a specific PCR-RFLP 
analysis as described earlier (Sunbul & Leblebicioglu; 2005). Since genotype F was not 
detected in this study,  the aforementioned PCR-RFLP analysis  for discrimination of 
genotypes F and H was not performed and thus is not described here.
The second-round PCR was performed by adding 1 µl aliquot of the first-round PCR 
product (diluted 1:10 with DEPC-dH2O) to each of two tubes (Mix A and Mix B), each 
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containing  5  µl  of  5X  GoTaq  buffer  containing  1.5  mM  MgCl2,  0.25  mM  of 
deoxynucleotide triphosphate mix, 0.3 µM of each mix A or mix B primers, 1U of Taq 
DNA polymerase in a 25 µL -reaction.  Negative PCR control was included in each 
reaction to ensure the specificity of genotyping results. Thermal cycling was performed 
for  35  cycles  with  the  following parameters:  preheating  at  95ºC for  3  minutes,  15 
cycles, with each cycle consisting of denaturation at 94ºC for 20 seconds, annealing at 
60ºC for  20 seconds,  and extension at  72 ºC for 30 seconds,  and an additional  20 
cycles, with each cycle consisting of denaturation at 94ºC for 20 seconds, annealing at 
58ºC for 20 seconds, and extension at 72ºC for 30 second. 
II .2.7.2 Determination of HBV genotype G by nested primer-specific PCR 
For  detection  of  HBV  genotype  G,  a  nested-PCR  targeting  the  core  region  was 
performed. The first round PCR amplified a 511-bp fragment in the core region using 
the outer primers HBV-1606S (the primer HBV-1606S sequence was provided kindly 
by  Professor  Chee  Kent  lim,  Monash  University,  Malaysia)  and  HBV-2094A 
(described in this study). The second-round or nested PCR was a multiplex PCR and 
used 3 primers  HBV-1653 /sense,  HBV-2039A /antisense and HBHKR2 /antisense. 
The primer pair HBV-1653 and HBV-2039 amplifies a 406-bp fragment (lindh, et al., 
1996), which serves as an internal control for the multiplex PCR. While the HBHKR2 
primer (Kato, et al., 2002) was designed based on genotype G-specific 36-bp insertion 
in  the core  region and in  combination  with the  common primer  HBV-1653 primer 
amplifies a 285-bp fragment. 
For the first round-PCR, 2 µl of DNA extracts were subjected for PCR essentially as 
described for first-round PCR of S/preS region in the previous section (II.2.7.1), with 
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0.3 μM of each of the primer pair HBV-1606S and HBV-2039A. Thermal cycling was 
performed with the following parameters: preheating at 94ºC for 3 minutes, 40 cycles, 
each  consisting  of  denaturation  at  94ºC  for  30  seconds,  annealing  at  54ºC  for  30 
seconds and extension at 72ºC for 40 seconds, and a final extension step at 72ºC for 5 
minutes. The second-round multiplex PCR of genotype G reaction was run as described 
for the second-round PCR of S/preS region with 0.3µM of each of the nested primers 
HBV-2039A/antisense,  HBV-1653/sense  and  HBHKR2/antisense.  Thermal  cycling 
included: preheating at 94ºC for 3 minutes, 35 cycles each consisting of denaturation at 
94ºC for 1 minute,  annealing at  55ºC for 30 seconds and extension at  72ºC for 40 
seconds, followed by a final extension at 72ºC for 5 minutes. 
For  analysis  of  genotyping  PCR  products,  the  respective  PCR  products  were 
electrophoresed on a 2 % or 3 % agarose gel prepared in 1X TBE buffer and containing 
ethidium bromide (0.5 μg/ml) and run at 5-8 V/cm. The HBV genotype-specific DNA 
fragments  were  determined  by  comparison  with  a  50-bp  or  100-bp  DNA  ladder 
(Promega, USA). The gels were visualized under UV illumination.
II .2.8 Detection of pre-core and core promoter mutants 
All HBV samples were subjected for mutation analysis for the three common mutations 
that occur within the core region: the basal core mutations (A1762/G1764> T1762/1764A), 
the  codon  15  varaints  (C1858/T1858)  and  precore  stop  muatation  at  codon  28 
(G1896A, TGG>TAG). These three mutations were analysed by nested RFLP-PCR. 
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For this purpose, the first-round PCR was performed using the primer pair HBV-1606S 
and HBV-2094A as described for the internal control used in the detection of genotype 
G (see previous section II.2.7.2).
The validity of restriction enzyme digestion was checked by digesting the two plasmids 
pMT2-FVIII -BDD (11000 bp) and pEGFP-C1 (4731 bp) with the three enzymes used 
for analysis of the above mentioned three mutations in the core gene, namely,  BfuCI, 
EcoNI and  Bsu36I. Analysis of plasmid digestion products showed that the digestion 
conditions used in this study are appropriate.
II .2.8.1 Basal core promoter mutations (A1762/G1764 > T1762/1764A) analysis 
Ten µl of the second PCR product (406 bp fragment)  of the genotype G/ internal 
control was digested with 1.2 U of the BfucI enzyme (New England Biolabs) at 37°C 
overnight.  The digestion products were analyzed  on a 3 % agarose gel.  The PCR 
amplicon  contained  a  wild  type  restriction  site  in  addition  to  mutant  specific 
restriction site and thus served as a control for the BfuCI digestion reaction. 
  II.2.8.2 Codon 15 mutation (C1858/T1858) analysis
The nested second-round PCR for detection of C1858/T1858 variants was performed 
using  the  common  primer  HBV-1680S and  the  specific  primer  HBV-1888A.  The 
primer  HBV-1888A contains  a mismatch at  nts  -8 to -6 (5’TGA3’ > 5’CCT3’) to 
generate an EcoNI restriction site in the PCR amplicon. The PCR amplicon (208bp) 
32
was digested with 3 Units of  EcoNI (New England Biolabs) at 37°C overnight. The 
digestion products were analyzed on a 3% agarose gel. 
II .2.8.3 Pre -core stop codon mutation (TGG>TAG at Codon 28) analysis 
The  nested  second-round  PCR  for  detection  of  A1896G  mutation  (codon  28  stop 
mutation or TGG>TAG) was performed using the common primer HBV-2039A and 
the specific primer HBV-1865S. The primer HBV-1865S contains a mismatch at nt -3 
(T>C) to generate a  Bsu36I restriction site in the PCR amplicon. The PCR amplicon 
(194  bp)  was  digested  with  2  Units  of  Bsu36I (New  England  Biolabs)  at  37°C 
overnight. The digestion products were analyzed on a 3 % agarose gel. 
II .2.9 DNA Sequencing and sequence analysis
The validity of primer-specific nested-PCR for HBV genotyping was verified by DNA 
sequencing of representative samples of each genotype. Additionally, the RFLP-PCR 
analysis results of precore/core region mutations were verified by DNA sequencing of 
representative samples. 
II. 2.9.1 HBV–DNA purification
The HBV amplicon of different genotypes was cleaned from the residual dNTP's and 
primers using a commercial DNA gel extraction kit (Wizard® SV Gel and PCR Clean 
UP System,  Promega,  USA).  Purification  was  processed  from gel  slices  following 
electrophoresis, the DNA band was excised from gel in a 1.5 ml microcentrifuge tube, 
mixed with 10 µL of membrane binding solution (4.5M guanidine isothiocyanate, 0.5M 
potassium acetate, pH 5) per 10 mg of gel, and incubated at 50-65ºC until the gel slice 
is  completely  dissolved.  Binding  of  DNA  to  SV-Minicolumn  was  achieved  by 
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centrifugation  at  14000  rpm  for  1  minute  followed  by  two  times  washing  with 
membrane washing solution (10 mM potassium acetate, pH 5; 80 % ethanol, 16.7 M 
EDTA, pH 8). The DNA was eluted with 50 µl of nuclease- free water.  
II .2.9.2 HBV–DNA sequencing
Following preparation of the PCR products or sequencing templates, the target DNA 
fragment was purified using a DNA gel extraction kit as described above (see section 
II.2.9.1) and the purified products accompanied by the specific  primers (see below) 
were  sent  for  sequencing  to  a  commercial  DNA  sequencing  facility  at  Bethlehem 
University (Bethlehem), and Metabion (Jerusalem). DNA sequencing was performed 
by  the  dideoxy  chain  termination  method  using  the  Big  Dye  Terminator  Cycle 
Sequencing  Ready  Reaction  Kit  (Applied  Biosystems)  and  the  automated  DNA 
Sequencer 3100 / Genetic Analyzer (Applied Biosystems) per the recommendations of 
the manufacturer.
For sequencing of the PCR products of the different HBV genotypes, two strategies 
were used. The first strategy used an amplicon generated by the primers YS1-S (nts 203 
to  221)  and S1-2  (nts  685  to  704)  which  amplifies  a  502-bp  fragment.  The  latter 
product has been used in previous studies for HBV genotyping by DNA sequencing 
(Zeng,  et  al.,  2004).  The  second  strategy  used  the  shorter  genotype-specific  PCR 
products. The specific primers used and the type of template used for sequencing are 
shown in Table 5. The amplification of the 502-bp amplicon, was performed using 2 μl 
of first-round PCR for HBV genotyping (see sections II.2.9.1 & 2), 0.3 μM of each 
primer  YS1-S  and  S1-2  under  the  same  conditions  used  for  second-round  PCR 
described in section II.2.7.1 While for the second strategy, the genotype-specific PCR 
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products were prepared as described for the genotyping reaction, purified and used for 
sequencing.
However,  for  sequencing the core region covering the three mutations  described in 
section II.2.8, a 406-bp fragment was amplified using the primer pair HBV-1653S and 
HBV-2039A, as described in section II.2.8.
For DNA sequencing, briefly, the appropriate PCR product (about 100 ng) was mixed 
with 3.2 pmol of the sequencing primer (shown in table 5) and 8 μl of the BigDye ready 
reaction mix in a final volume of 20 μl. The thermal cycling of the cycle sequencing 
step was performed using the following program: preheating at 95°C for 5 minutes and 
30 cycles each consisting of denaturation at 95°C for 30 seconds, annealing at 50°C for 
10 seconds, and extension at 60°C for 4 minutes. Excess dye terminators were removed 
from the sequencing mixture by means of ethanol/sodium acetate precipitation. Heat-
dried samples were dissolved in 10 μl of nuclease-free distilled water and loaded onto 
the DNA sequencer according to the manufacturer’s instructions.
Table 5.  Primers used for DNA sequencing.
Sample name Primer name & type PCR product size (bp)
174 BA1R 68
128 BA1R 68
100 BB1R 281
126 BB1R 281
111 BD 119 
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126 BC1R 122
100 BC1R 122
67 YS1-2 502
116 YS1-2 502
174 YS1-2 502
31 YS1-2 502
116 YS1-2 502
29 YS1-2 502
115 HBV-2039 406
114 HBV-2039 406
129 HBV-2039 406
II. 10 Phylogenetic and statistical analysis
The phylogenetic analysis was made on the amplified products of S gene as indicated 
in Table 5. The sequencing data were aligned with reference strains retrieved from the 
Gene Bank database, subtype A: X02763, X51970, AF090842; subtype B: D00329, 
AF100309; subtype C: X04615, M12906, AB014381; subtype D: X65259, M32138, 
X85254; subtype E: X75657, AB032431; subtype F: X69798, AB036910, AF223965; 
subtype  G:  AF160501,  AB064310,  AF405706;  subtype  H:  AY090454,  AY090457, 
AY0900460,  as  well  as  genomes   representing  the  different  prototypes  of  HBV 
genotypes (Genotype A: AB014370, Genotype B: AB033554; Genotype C: AB014365; 
Genotype  D:  X97848;  Genotype  E:  X75664;  Genotype  F:  X75663;   Genotype  G: 
AF160501; Genotype H: AB059659. The Gene bank accession numbers of the HBV 
prototypes were provided kindly by Professor Hideaki Kato (Nagoya City University, 
Japan). Sequence alignment was performed using the CLUSTAL 1X (1.81) program, 
while  the  GENE  doc  program  version  (2.7)  was  used  for  exporting  the  aligned 
sequences and producing edited sequence to the PHYLIP program. 
II.10.1 Phylogenetics
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The PHYLIP program was used in a sequential way. The output from the first program 
was used as an input in the next program.  Phylogenetic analysis of S gene sequences 
was  performed  using  the  PHYLIP  package,  version  (3.6).  The  PHYLIP  program 
SEQBOOT was used to bootstrap data in which 100 data sets were analyzed. First a 
distance matrix was calculated by Dnadist from the  multiple sequence alignment. The 
matrix was then transformed into a tree by a NEIGHBOR (neighbor joining) to create 
dendrograms. Consense was used to create consensus trees from multiple trees. Finally, 
Trees were finalized by tree view program version (1.0).
II.10.2 Statistical analysis
All data analyses were performed using the SPSS package v.15 (SPSS Inc., Chicago, 
USA). Data are shown as means ± SD. All continuous data were analyzed by One Way 
ANOVA. While all the independent variables were analyzed by Chi Square and Binary 
Logistic Regression. A p-value <0.05 was considered statistically significant.
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Appendix 1
Hepatitis B Questionnaire
Personal Information:
Patient Name:  Date of Birth: _________
Place of Birth: Sex: M  F 
District: Phone:
Place of residence:  1.city                   2.village                     3.camp
Occupation: _________
Total monthly income (JD) 1-   0-500    2-    500-1000   3-     1000-2000 
4- >2000
Number of persons/ family
Date reported to public health: ___/____/____
 
Clinical and diagnostic data: 
1-Reason for HBV testing: (check all items that apply) 
□ Asymptomatic (with risk factors)     □ Asymptomatic without risk factors/Prenatal 
□ Blood/organ donor screening
□ Symptoms of acute hepatitis           □ Evaluation of elevated liver enzymes
□ Follow-up testing for previous marker of viral hepatitis  
     
2 - Was the patient hospitalized for hepatitis?     □Yes              □No
3- Did the HBV patient develop HBV complications? 
□Cirrhosis        □HCC                     □Liver Failure        □ Hepatic Encephalopathy 
□ Coma 
                
4-If the patient has HBV complications, what confirmatory tests were done to 
investigate these complications?  
 □ Alpha- Fetoprotein      □ Ultrasound   □ Liver Biopsy 
5- Did the patient die from hepatitis?   □Yes                            □No
Date of death: ___/___/____ 
Laboratory diagnostic tests:
CBC result:
WBC_________    RBC_________ Platelets Count_________  
Date for first blood sample drawn for hepatitis B testing?  __/__/__ 
Reporting Laboratory:______________________________________
Liver enzyme values: 
SGPT (ALT) __________ Test date: ___/___/____ Upper limit normal: _______ 
SGOT (AST) __________ Test date: ___/___/____ Upper limit normal: _______ 
Other tests __________________________________________________
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HBV serology results:  
Test Positive Negative Borderline Not Done
HBsAg
Anti- HBs
HBe 
Anti_ HB e 
total anti-HBc
IgM anti-HBc
PCR result for detection of HBV DNA in serum: 
__________________________
Vaccination history:  
1-Has the patient ever received the hepatitis B vaccine? □Yes         □No  
If yes, how many doses? □ 1 □ 2 □ 3+ 
2-In what year was the last dose received? ______________________ 
3-Was the patient ever tested for antibody to HBsAg (anti-HBs) within 1-2 months 
after the last dose?         □ Yes             □ No 
4-Was the patient ever given Immune Globulin for HBV? □ Yes        □ No 
If yes, at what month/year was the last dose received?______________________ 
Mode of transmission:    
□ Blood Transfusion          □ Perinatal          □Sex Partner 
□Hemodialysis   □Household Member (non-sexual)            □ IDU
□Nosocomial.
1-Did the patient experience an accidental stick or puncture with a needle or other 
objects contaminated with blood?      □Yes              □No
2-Did the patient receive a tattoo?        □Yes                  □ No 
3-Did the patient has any part of his body pierced (other than ear)?  □Yes     □No
4-Did the patient has a minor surgery (other than oral treatment)?  □Yes    □ No 
Antiviral treatment:                       
1-Type of treatment __________________________
2-Date for starting treatment__________________________ 
3-Duration of treatment __________________________
Interviewer name: __________________________ 
Interview Date: ___/___/___ 
Name of health center/clinic: 
______________________________________ 
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